Многоцелевые лекарственные препараты: новые 2025 и послерыночного контроля за безопасностью наркотиков, 2022-2024.

Introduction

Polypharmacology is an emerging strategy of design, development, and clinical implementation of multi-target-directed ligands (MTDLs) i.e., agents capable of modulating two or more molecular targets simultaneously [ 1 , 2 ]. This approach, which emerged beyond the classical ‘one drug-one target’ paradigm, is particularly relevant in the context of complex diseases, such as cancer, neurodegenerative disorders, inflammatory and cardiovascular diseases, where the involvement of multifaceted etiological components limits the effectiveness of single-target-based therapies [ 2 , 3 ]. The demand for such innovative medications is increasing also due to limits in clinical efficacy, the occurrence of adverse drug reactions (ADRs), and multidrug resistance, especially seen in the context of infectious diseases [ 4 ] and cancer [ 3 , 5 , 6 ].

In guiding multi-target drug design, the integration of omics data, clustered regularly interspaced short palindromic repeats (CRISPR) functional screens, and pathway simulations plays a pivotal role in target selection and multi-target ligand prediction [ 7 ]. Assumptions of network pharmacology enable the construction of drug-target networks [ 8 ]. Artificial intelligence (AI) algorithms offer deep generative models along with scalable and versatile platforms able to identify potential drug targets, predict the efficacy, and optimize lead compounds [ 9 , 10 ]. Along with the approach of machine learning, they facilitate the generation of molecules with the most optimal balance between potency, selectivity, and safety [ 10 ]. For example, at the early stage of the development of kinase inhibitor candidates, selectivity profiles are typically obtained, and non-kinase off-target inhibitory activity is predicted [ 11 ]. However, the dynamic, self-learning nature of AI systems needs full regulatory guidance, continuous validation, and ethical oversight to enable trustworthy AI deployment in the design of next-generation multi-target compounds [ 10 ].

On the one hand, polypharmacology offers the chance to reduce ADRs and improve patient compliance in comparison to ‘classic’ combination therapies, based on highly selective ligands [ 7 , 12 ]. This can be achieved not only due to a generally more predictable pharmacokinetic profile of MTDLs than of drug combinations, but also due to the advantage of using a single formulation and simplification of dosing regimens [ 13 , 14 ]. Additionally, complementary synergistic effects may permit the desired therapeutic outcome to be achieved at lower doses of multi-target agents, potentially minimizing the risk of ADRs. On the other hand, engagement of MTDLs raises safety concerns. Off-target effects , an inherent consequence of the promiscuous nature of those molecules, might contribute to adverse reactions that are not fully predictable from preclinical in vitro and in vivo models or early-phase clinical trials [ 14 ]. Such effects may arise from the convergence of pharmacodynamic interactions or tissue-specific target expression, particularly in (highly) heterogeneous patient populations. These challenges emphasize the critical importance of post-marketing drug safety surveillance, as even comprehensive pre-approval evaluations may fail to identify rare, delayed, or population-specific ADRs [ 15 ]. Moreover, fast-track approvals, especially in the case of drugs with orphan designation (see glossary in Table 1 ), are associated with more unreported ADRs, along with more frequent post-marketing safety updates [ 16 ]. Real-world pharmacovigilance systems – incorporating spontaneous reporting databases, electronic health records, and large-scale observational studies – are therefore essential to detect safety signals that emerge only after widespread clinical exposure [ 17 ]. Table 1 Glossary of selected terms of the present article Item Explanation References Breast cancer tumor markers The occurrence of HR and the HER2/neu marker in breast cancer has prognostic and therapeutic relevance. HR-positive breast cancer accounts for 70% of the cases and can be treated specifically by many procedures including inavolisib (Table 2 ). HER2-positive breast cancer accounts for 15–20% of the cases and has a poorer prognosis than HR-positive breast cancer but can be specifically treated with drugs like datopotamab deruxtecan (Table 2 ) and trastuzumab deruxtecan (Table 3 ). Triple-negative breast cancer accounts for 10–15% and on the rule has a poor prognosis. [ 18 ] CRS … is a systemic hyperinflammatory response that is characterized by fever, hypotension, and hypoxia and can lead to organ dysfunction. CRS occurs due to the activation and proliferation of multiple immune cell types, including T-cells … and the subsequent release of pro-inflammatory cytokines. IL-6 signaling plays a central role in the pathophysiology of CRS by activating vascular endothelial cells. [ 19 ] ICANS … is characterized by confusion, reduced consciousness level, aphasia, raised intracranial pressure, and seizures. It is thought to be caused by cytokine-mediated endothelial activation and disruption of the blood-brain barrier. It therefore typically occurs alongside CRS but can occur after CRS has resolved. [ 19 ] Myasthenia gravis … is a rare autoimmune disease that causes debilitating muscle weakness due to impaired neuromuscular transmission. The standard medical therapy consists of symptomatic treatment with acetylcholinesterase inhibitors (e.g., pyridostigmine) and immunomodulating agents (e.g., corticosteroids). New strategies include complement blockade (i.e., eculizumab, ravulizumab, and zilucoplan ) and neonatal Fc receptor antagonism (i.e., efgartigimod and rozanolixizumab). [ 20 ] Orphan drug Orphan drugs undergo an expedited approval procedure by the regulatory authority in charge (e.g., FDA or EMA). In the case of EMA, orphan drug designation is possible if the corresponding disease is less frequent than 5 per 10,000 inhabitants. Phase 3 studies may be based on non-randomized open-label single-arm trials, studying only half of the patient population enrolled in non-orphan trials. There is a user fee reduction, scientific advice by the EMA and an extended market exclusivity for a period of 10 years. [ 16 ] PML … is a rare but often fatal demyelinating disease of the central nervous system caused by JCV. Natalizumab, a drug used for advanced stages of multiple sclerosis, is a prototypical drug leading to this disease. [ 21 ] Severity of adverse events (side effects) According to the National Cancer Institute, adverse events (side effects) are classified as: grade 1 – mild; grade 2 – moderate; grade 3 – severe; grade 4 – life-threatening, and grade 5 – death related to adverse event. [ 22 ] CRS, cytokine release syndrome; EMA, European Medicines Agency; Fc, fragment crystallizable region of an antibody; FDA, Food and Drug Administration; HER2/neu, receptor tyrosine kinase within the erb-b2 family; HR, hormone receptors (estrogen and progesterone receptors); ICANS, immune effector cell-associated neurotoxicity syndrome; IL-6, interleukin 6; JCV, human polyomavirus 2; PML, progressive multifocal leukoencephalopathy

In the context of polypharmacology, post-marketing safety surveillance represents an especially strategic role. The broader target profile of such agents may lead to complex adverse event patterns that may require advanced AI-driven methodologies and network-based safety analyses [ 23 , 24 ]. Moreover, due to expedited approvals, many novel anti-cancer drugs (which account for the majority of newly marketed MTDLs) are considered clinically immature [ 17 ]. Continuous benefit-risk reassessment, supported by real-world evidence, enables the early identification of their unpredicted interactions with unexpected targets and gives the chance to implement risk minimization strategies, labeling updates, and potential dose adjustments [ 15 , 24 ].

This paper is the third one in a series of communications dedicated to multi-target drugs approved by the European Medicines Agency (EMA) in the years 2022 to 2025. In the first paper (Ryszkiewicz et al., 2023 [ 12 ]), we thoroughly described the principles of polypharmacology and compared the anticipated clinical benefits of MTDLs with those of ‘classical’ combination therapy employing selective drugs (for other recent reviews see Abdelsayed, 2025 [ 7 ]; Manen-Freixa and Antolin, 2024 [ 25 ]). We also provided a list of multi-target drugs authorized by the EMA and marketed in Germany in 2022. In the subsequent paper (Ryszkiewicz et al., 2025 [ 13 ]), this list was extended to the years 2023 and 2024. The current review provides an update for 2025 and, in addition, a summary of post-marketing drug safety surveillance studies regarding the MTDLs marketed in the years of 2022, 2023, and 2024.

New multi-target drugs in 2025

In 2025, 38 new drugs were authorized by the EMA and marketed in Germany and other European Union (EU) countries [ 26 , 27 ]. A more detailed analysis revealed that 11 can be classified as multi-target compounds (Table 2 ). Nine out of them are indicated for tumor treatment (#1-#9), one for the prophylaxis of migraine (#10), and one for the treatment of peripheral thyrotoxicosis (#11). Antitumor drugs can be divided into three main categories, according to the classification listed in Ryszkiewicz et al. (2025) [ 13 ]. Drugs #1 and #2 are antibody-drug conjugates (ADCs). The antibody domain enables targeted delivery of a linked cytostatic agent to cells that express a specific surface protein, thereby enhancing therapeutic efficacy, reducing adverse effects, and potentially overcoming tumor resistance to chemotherapy. Drugs #3 and #4 are bispecific antibodies. By concurrently targeting cancer cells and T lymphocytes, they activate cytotoxic T-cells to respond against the tumor (T-cell engagers). Drugs #5-#9 are low-molecular-weight organic compounds that inhibit enzymes like protein kinases. By inhibiting dysregulated target proteins, these molecules block aberrant signaling pathways responsible for uncontrolled tumor cell proliferation and survival. Table 2 New multi-target drugs introduced in Germany in 2025 1 No. INN (brand name) ATC code Short description Molecular mechanisms Indication(s) References Degree of innovation 2 Additional benefit 3 1. Datopotamab deruxtecan (Datroway ® ) L01FX35 antibody-drug conjugate antibody (b) TROP2 unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received endocrine therapy and at least one line of chemotherapy in the advanced setting [ 28 , 29 ] 1 Ø DXd (-) topoisomerase I 2. Tisotumab vedotin (Tivdak ® ) L01FX23 antibody-drug conjugate antibody (b) TF on the surface of tumor cells recurrent or metastatic cervical cancer in adult patients with disease progression on or after systemic therapy [ 30 , 31 ] 3 Ø vedotin (-) polymerization of microtubules 3. Linvoseltamab (Lynozyfic ® ) not yet assigned bispecific antibody (b) BCMA on malignant MM B-lineage cells relapsed and refractory MM in adult patients who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy [ 32 , 33 ] 1 Ø (b) CD3 on cytotoxic T cells 4. Odronextamab (Ordspono ® ) L01FX34 bispecific antibody (b) CD20 on malignant B cells relapsed or refractory follicular lymphoma and DLBCL in adult patients after two or more lines of systemic therapy [ 34 , 35 ] 1 Ø (b) CD3 on cytotoxic T cells 5. Repotrectinib (Augtyro ® ) L01EX28 kinase inhibitor (-) ROS1 (-) TRKA (-) TRKB (-) TRKC (-) ALK (i) ROS1-positive advanced NSCLC in adult patients (ii) Advanced solid tumors expressing an NTRK gene fusion in adult and pediatric patients ≥ 12 years of age, who: have received a prior NTRK inhibitor, or have not received a prior NTRK inhibitor, and treatment options not targeting NTRK provide limited clinical benefit, or have been exhausted [ 36 , 37 ] 2 Ø Ø 6. Erdafitinib (Balversa ® ) L01EN01 kinase inhibitor (-) FGFR (all isoforms, including FGFR2 and FGFR3) unresectable or metastatic urothelial carcinoma in adult patients with susceptible FGFR3 genetic alterations who have been previously treated with at least one line of therapy containing a PD-1 or PD-L1 inhibitor [ 38 ] 2 Ø 7. Mirdametinib (Ezmekly ® ) L01EE05 kinase inhibitor (-) MEK1 (-) MEK2 symptomatic, inoperable plexiform neurofibromas in patients with neurofibromatosis type 1, aged ≥ 2 years [ 39 , 40 ] 2 + nq 8. Inavolisib (Itovebi ® ) L01EM06 enzyme inhibitor (-) p110α (+) degradation of mutated p110α PIK3CA -mutated, estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, in combination with palbociclib and fulvestrant, following recurrence on or within 12 months of completing adjuvant endocrine treatment who had been (i) treated (ii) not treated with a CDK4/6 inhibitor (e.g., palbociclib) [ 41 , 42 ] 2 Ø ++ 9. Vorasidenib (Voranigo ® ) L01XM04 enzyme inhibitor (-) IDH1 (-) IDH2 predominantly non-enhancing grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged ≥ 12 years and weighing ≥ 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy [ 43 , 44 ] 2 + nq 10. Atogepant (Aquipta ® ) N02CD07 antagonist of G protein-coupled receptors (-) several receptors of calcitonin/CGRP-receptor family prophylaxis of migraine in adults who have ≥ 4 migraine days per month [ 45 , 46 ] 2 Ø 11. Tiratricol (Emcitate ® ) H03AA04 thyroid hormone metabolite (+) TRα (+) TRβ peripheral thyrotoxicosis in patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome), from birth [ 47 , 48 ] 3 + nq 1 in countries in which other regulatory authorities are in charge (e.g., Food and Drug Administration (FDA) for the USA), drugs might have reached approval earlier or an additional indication might have been assigned 2 degree of innovation according to Pharmazeutische Zeitung : 1 – me-too preparation; 2 – step innovation; 3 – disruptive innovation 3 evaluation by the Joint Federal Committee (Gemeinsamer Bundesausschuss): additional benefit was considerable (++), could not be quantified in terms of minor, considerable or major ( + nq ) or was absent ( Ø ) ALK, anaplastic lymphoma kinase; ATC, anatomical therapeutic chemical classification; BCMA, B-cell maturation antigen; CD3, 20, 38, cluster of differentiation 3, 20, 38; CDK4/6, cyclin-dependent kinase 4/6; CGRP, calcitonin gene-related peptide; DLBCL, diffuse large B-cell lymphoma; DXd, deruxtecan; FGFR(2, 3), fibroblast growth factor receptor (2, 3); HER2, human epidermal growth factor receptor 2; HR, hormone receptors (estrogen and progesterone receptors); IDH1, 2, isocitrate dehydrogenase 1, 2; INN, international nonproprietary name; MCT8, monocarboxylate transporter 8; MEK1, 2, mitogen‑activated protein kinase 1, 2; MM, multiple myeloma; NSCLC, non-small cell lung cancer; NTRK, neurotrophic receptor tyrosine kinase; PIK3CA , p110α, phosphatidylinositol-4,5-bisphosphate-3-kinase catalytic subunit alpha gene /protein; PD-1, programmed death receptor 1; PD-L1, programmed death receptor 1 ligand 1; ROS1, ROS proto-oncogene 1 receptor tyrosine kinase; TF, tissue factor; TRα, β, thyroid hormone receptors α, β; TRKA, B, C, tropomyosin receptor tyrosine kinase A, B, C; TROP2, trophoblast cell surface antigen 2; (+), activates; (-), blocks; (b) binds to

Breast cancer, characterized by significant heterogeneity, is one of the main causes of malignancy-related deaths in women [ 49 ]. A better understanding of its mechanisms of tumorigenesis and progression contributed to advancements in treatment strategies and the development of novel treatment approaches, which support the idea of precision oncology and personalized medicine [ 49 , 50 ]. ADCs perfectly meet this concept, giving a chance to targeted delivery of a given cytostatic molecule directly to cancer cells expressing a certain marker on their surface and minimizing the risk of systemic side effects [ 51 , 52 ]. Trophoblast cell surface antigen 2 (TROP2), a type I transmembrane glycoprotein, is overexpressed in numerous types of tumors, including all forms of breast cancer [ 53 ]. The first-in-class anti-TROP2 ADC, sacituzumab govitecan, a third-line treatment option for unresectable or metastatic triple-negative or hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer (see glossary in Table 1 ) in adult patients, was authorized by the EMA in 2021 [ 54 ]. Another TROP2-directed ADC, datopotamab deruxtecan (Datroway ® ; #1, Table 2 ; Fig. 1 ), also shows notable efficacy and a tolerable safety profile [ 28 , 29 , 55 ]. Datopotamab, a humanized anti-TROP2 IgG1 antibody, is attached to the topoisomerase I inhibitor deruxtecan (DXd) via a tetrapeptide-based protease-cleavable linker (Fig. 1 ). Such a conjugate is stable in human plasma. After binding to TROP2 expressed on the surface of tumor cells, datopotamab deruxtecan is internalized, and subsequently DXd is released, which results in DNA damage and cellular apoptosis [ 55 ]. Like many other ADCs, datopotamab deruxtecan may exhibit cytotoxic effects indirectly, via antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and the bystander cytotoxic effect of DXd on TROP2-positive tumor cells and adjacent surrounding cells. The most prevalent side effects of datopotamab deruxtecan (affecting more than 1 in 10 people) include stomatitis, nausea, and fatigue [ 29 ]. Fig. 1 Chemical structure of datopotamab deruxtecan, an antibody-drug conjugate with linked pharmacophores indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Datopotamab (a humanized IgG1 monoclonal antibody) is covalently bound to deruxtecan (DXd, an exatecan derivative), a topoisomerase I inhibitor (blue rectangle, broken line) via a tetrapeptide-based (gly-gly-phe-gly) cleavable linker (green parentheses). Approximately 4 DXd molecules are attached to each antibody molecule [ 28 ]

Cervical cancer, similarly to breast cancer, remains a significant contributor to cancer incidence and mortality among women worldwide, with an estimated 660,000–670,000 new diagnoses and 300,000–350,000 deaths per year in the early 2020s [ 56 ]. Human papillomavirus (HPV) infection is a leading yet preventable cause of this condition, in addition to alterations in cell proliferation signaling, and tumor immune microenvironment modulation [ 57 ]. In the setting of metastatic and/or recurrent disease, immune-checkpoint inhibitors (e.g., pembrolizumab), anti-angiogenic agents (e.g., bevacizumab), and ADCs are considered as treatment options [ 58 ]. Tisotumab vedotin (Tivdak ® ; #2, Table 2 , Fig. 2 ), a representative of the latter agents, consists of an anti-tissue factor (TF) IgG1 antibody attached to monomethyl auristatin E (MMAE), a microtubule-disrupting agent (Fig. 2 ). After binding of the tisotumab domain to TF, expressed at elevated levels on a plenitude of solid tumors, including cervical cancer, the whole ADC-TF complex is internalized. Then, MMAE is released via proteolytic cleavage. Disruption of the microtubule network of actively dividing cells leads to the arrest of the cell cycle and apoptotic cell death [ 30 , 31 ]. Besides its direct cytotoxic effect in TF-expressing tumor cells, tisotumab vedotin also causes ADCC, ADCP, bystander cytotoxicity, and immunogenic cell death. The most frequently reported ADRs of tisotumab vedotin comprise peripheral neuropathy, nausea, nosebleed, conjunctivitis, hair loss, anemia, and diarrhoea [ 31 ]. Fig. 2 Chemical structure of tisotumab vedotin, an antibody-drug conjugate with linked pharmacophores indicated for the treatment of recurrent or metastatic cervical cancer. Tisotumab (a humanized IgG1 kappa anti-tissue factor (TF) monoclonal antibody) is covalently bound to vedotin (brown rectangle, broken line), i.e., the microtubule-disrupting agent monomethyl auristatin E (MMAE) (blue rectangle, broken line), attached via a p -aminobenzoic acid (PABA) moiety (grey rectangle, broken line) and a dipeptide-based (val-cit, green parentheses) cleavable linker to IgG1 antibody [ 30 ]

Bispecific antibodies are an emerging immunotherapy approach in the treatment of multiple myeloma (MM), a hematologic malignancy marked by the uncontrolled proliferation of plasma cells within the bone marrow along with the overproduction of monoclonal antibodies [ 59 – 61 ]. MM rapidly acquires resistance to currently available chemotherapy options, making additional or substitute therapies essential. In recent years, three IgG4-based bispecific antibodies, i.e. talquetamab, teclistamab, and elranatamab, have reached the market authorization by the EMA [ 13 , 60 ]. Linvoseltamab (Lynozyfic ® ; #3, Table 2 ) is another IgG4-based fourth-line treatment option for patients with refractory or relapsed MM [ 32 ]. By simultaneous binding (i) to the B-cell maturation antigen (BCMA) on the surface of malignant MM B-lineage cells, late-stage B-cells, and plasma cells, and (ii) to the cluster of differentiation 3 (CD3) protein on cytotoxic T cells, an immunological synapse is created. This results in T-cell activation and lysis of targeted cells, regardless of the major histocompatibility complex (MHC) class I molecules on antigen-presenting cells or T-cell receptor specificity [ 33 ]. Although teclistamab and elranatamab share an analogous mechanism of action, linvoseltamab offers comparable to slightly better efficacy with a favorable safety profile, according to cross-trial comparisons [ 62 , 63 ]. One of the most commonly reported side effects of linvoseltamab is cytokine release syndrome (CRS; typically associated with symptoms such as fever, tachycardia, hypoxia, and hypotension), which is related to the T cell-induced lysis of the targeted B cells (for glossary, see Table 1 ); other common side effects are musculoskeletal pain, neutropenia, and cough [ 33 ].

The development of bispecific antibodies marks a significant advancement also in the treatment of relapsed/refractory B-cell lymphomas, fulfilling critical therapeutic gaps for patients with limited conventional options [ 64 ]. Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma characterized by substantial molecular heterogeneity. Although available therapeutic regimens significantly improved outcomes in the last few years, relapses still occur in nearly 40% of patients [ 65 ]. Odronextamab (Ordspono ® ; #4, Table 2 ), a third-line treatment option for DLBCL, is a human IgG4-based bispecific antibody. Moreover, it is also indicated for the treatment of follicular lymphoma, an indolent yet incurable non-Hodgkin lymphoma [ 34 , 66 ]. Odronextamab binds to CD20 present on malignant B cells and CD3 on cytotoxic T cells, i.e., a CRS is also typical for this drug (Table 2 ); other main side effects of odronextamab encompass neutropenia, fever, and anemia [ 35 ].

Rearrangements in the proto-oncogene receptor tyrosine kinase ROS1 gene characterize a specific, therapeutically addressable group of non-small cell lung cancer (NSCLC), accounting for approximately 2% of cases, associated with non-smoker status, younger age, and frequently presenting with brain metastases [ 67 , 68 ]. Fusion proteins containing ROS1 or tropomyosin receptor tyrosine kinase (TRK) domains can promote tumor development by excessively activating downstream signaling pathways, resulting in uncontrolled cell growth [ 36 ]. The use of ROS1 tyrosine kinase inhibitors (TKIs) has markedly improved patient outcomes. Although first-generation drugs, such as crizotinib and entrectinib, demonstrate high response rates (over 60%-70%), their long-term effectiveness is restricted by resistance mutations and limited blood-brain barrier permeability [ 69 ]. Repotrectinib (Augtyro ® ; #5, Table 2 ; Fig. 3 ) potently inhibits ROS1, anaplastic lymphoma kinase (ALK), and TRK kinases (TRKA, TRKB, TRKC) and is indicated for the treatment of locally advanced and metastatic solid tumors, including NSCLC [ 37 ]. By binding inside the adenosine triphosphate (ATP)-binding pocket, it avoids steric interference from both gatekeeper and solvent-front mutations [ 36 , 37 ]. Repotrectinib shows activity in TKI-naïve and TKI-resistant tumors, expressing fusion oncogenes ROS1, TRKA, TRKB, TRKC, and their corresponding mutations (ROS1 G2032R , ROS1 D2033N , TRKA G595R , TRKB G639R , and TRKC G623R ) [ 36 , 69 ]. Moreover, its penetration to the central nervous system is vastly enhanced [ 68 , 69 ]. The most common side effects include dizziness, dysgeusia, constipation, paresthesia, anemia, and dyspnea [ 36 ]. Fig. 3 Chemical structures of the recently marketed multi-target-directed ligands (MTDLs): repotrectinib, erdafitinib, mirdametinib, inavolisib, vorasidenib, and atogepant

Urothelial carcinoma, the most prevalent cancer of the urinary tract, remains a major clinical challenge. Especially in its metastatic stage, prognosis still remains poor, despite ongoing advancements in treatment, with ADCs like sacituzumab govitecan and immune checkpoint inhibitors like pembrolizumab introduced as alternatives to the ‘traditional’ first-line platinum-based chemotherapy [ 70 ]. As many as 70% of low-grade non-muscle-invasive bladder cancers and 20‑40% of patients with advanced urothelial cancer exhibit somatic fibroblast growth factor receptor 3 (FGFR3) alterations [ 71 , 72 ]. This leads to the activation of downstream signaling pathways and subsequent cellular proliferation [ 71 ]. Erdafitinib (Balversa ® ; #6, Table 2 ; Fig. 3 ) is the first small-molecule pan-FGFR TKI approved in advanced bladder cancer [ 38 , 73 ] and represents an example of targeted therapy. By targeting the FGFR2 and FGFR3 receptors, along with their mutated forms, it inhibits FGF signaling, which results in cell death [ 73 ]. The most common side effects are hyperphosphatemia, diarrhea, stomatitis, and xerostomia (dry mouth) [ 38 ].

The NF1 gene encodes neurofibromin 1, a GTPase-activating protein that negatively regulates rat sarcoma virus GTPase (RAS) signaling [ 74 ]. Neurofibromatosis type 1, caused by mutations in the NF1 gene, is an autosomal-dominant condition and results in the formation of plexiform neurofibromas. These benign tumors of peripheral nerves, frequently associated with pain, disfigurement, and functional impairment, may progress into malignant peripheral nerve sheath tumors and cause substantial morbidity [ 74 – 76 ]. Mitogen‑activated protein kinase (MEK) inhibition remains the only approved treatment approach [ 74 ], with mirdametinib (Ezmekly ® ; #7, Table 2 ; Fig. 3 ), an oral small-molecule inhibitor of MEK1 and MEK2, being the first agent indicated both for adult and pediatric patient populations [ 39 , 40 ]. Loss of NF1 function results in sustained RAS activation and drives tumor growth [ 74 ]. Mirdametinib, an orphan drug (see glossary in Table 1 ), inhibits MEK activity within the RAS‑rapidly accelerated fibrosarcoma (RAF)‑MEK pathway, thereby suppressing growth and survival of tumor cells in which the RAF‑MEK‑extracellular signal-regulated kinase (ERK) pathway is activated [ 39 ]. Mirdametinib offers a significant advancement in the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, offering durable reduction of tumor volume, relief of pain, improved quality of life, and a tolerable safety profile [ 76 ]. The most commonly reported side effects are acneiform dermatitis, diarrhea, nausea, an increase in blood creatine phosphokinase, and musculoskeletal pain [ 39 ].

Mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha ( PIK3CA ) gene are common in breast cancer and lead to abnormal activation of the PI3K/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway, strongly implicated in tumorigenesis and drug resistance [ 77 , 78 ]. In estrogen-receptor positive, HER2-negative advanced breast cancer (see glossary in Table 1 ), dysregulation of this pathway is considered a key mechanism underlying resistance to endocrine therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, the first-line therapeutic options [ 78 ]. Inavolisib (Itovebi ® ; #8, Table 2 ; Fig. 3 ) is an inhibitor of the protein p110α, encoded by the PIK3CA gene. Additionally, it acts as a mutant degrader by promoting the degradation of mutated p110α [ 41 ]. Because of its dual mechanism of action, inavolisib suppresses the activation of downstream PI3K pathway mediators, including AKT, which results in a reduction of cellular proliferation and induction of apoptosis in breast cancer cells with PIK3CA mutations [ 41 , 42 ]. Among the side effects of inavolisib, the most common ones are hyperglycemia, stomatitis, diarrhea, and thrombocytopenia [ 42 ].

Mutations in genes encoding isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) enzymes lead to the overproduction of 2-hydroxyglutarate (2-HG), an oncogenic metabolite, which impairs cellular differentiation [ 43 , 79 ]. Within the spectrum of diffuse gliomas, IDH-mutant grade 2 tumors mainly affect young patients [ 80 ]. Despite their indolent growth pattern, they demonstrate persistent progression, and recurrence is almost inevitable [ 81 , 82 ]. Surgical resection remains the first-line intervention, followed by magnetic resonance imaging (MRI) surveillance in low-risk patients and radiochemotherapy in those at high risk [ 81 ]. Although these procedures improve overall survival, they may negatively impact cognitive function, quality of life, financial stability, employment, and overall independence [ 80 ]. The orphan drug vorasidenib (Voranigo ® ; #9, Table 2 ; Fig. 3 ), a highly brain-penetrant first-in-class inhibitor of mutant IDH1/2 enzymes, addresses the need for a novel approach that postpones disease progression and defers the use of radio- and chemotherapy [ 44 , 80 , 83 ]. By targeting the mutants of IDH1 and IDH2, vorasidenib reduces the excessive production of 2-HG, thereby leading to differentiation of malignant cells and reduction of their proliferation. The most common side effects observed after vorasidenib treatment are fatigue, diarrhea, and laboratory abnormalities (i.e., increased levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT)) [ 43 , 44 ].

Migraine is associated with increased plasma levels of calcitonin gene-related peptide (CGRP), a neuropeptide that functions as a strong vasodilator and contributes to the modulation of pain [ 45 , 84 ]. Several monoclonal antibodies directed against CGRP (galcanezumab, fremanezumab, and eptinezumab) or its receptor (erenumab) and small-molecule CGRP receptor antagonists (rimegepant) indicated for migraine prophylaxis and/or acute treatment have reached the market recently [ 84 , 85 ]. The latter drugs are highly selective ligands, whereas in the case of atogepant (Aquipta ® ; #10, Table 2 ; Fig. 3 ), modulation of more than one calcitonin/CGRP-receptor family member could be involved in its pharmacological effects. Yet, the exact biological mechanism responsible for atogepant’s role in migraine prevention has not been definitively identified [ 46 ]. Its most common adverse reactions are nausea, constipation, and fatigue/somnolence [ 46 , 86 ].

Monocarboxylate transporter 8 (MCT8) deficiency is a rare X-linked genetic condition stemming from mutations in the SLC16A2 gene [ 87 ]. Under physiological conditions, MCT8 is responsible for the transport of thyroid hormones, particularly triiodothyronine (T3), across the cell membrane into cells, thereby enabling their proper metabolic and developmental functions [ 88 ]. Mutations in the MCT8 gene lead to Allan-Herndon-Dudley syndrome, a condition marked by severe neurodevelopmental impairment and motor dysfunction caused by insufficient thyroid hormone levels in the brain, along with accompanying endocrine abnormalities resulting from chronic thyrotoxicosis due to elevated thyroid hormone levels outside the central nervous system [ 89 ]. The orphan drug tiratricol (Emcitate ® ; #11, Table 2 ; Fig. 4 ), an agonist of the thyroid hormone receptors TRα and TRβ, is a novel treatment option. As a metabolite of active thyroid hormone T3, it shares a high degree of structural similarity. Although its degradation (via deiodination and conjugation) and elimination (via bile and urine) follow the same pathway as T3, tiratricol is characterized by its different tissue specificity. Moreover, unlike T3 and L-thyroxine (T4), tiratricol is able to enter MCT8-dependent cells without a functioning MCT8. Therefore, tiratricol is able to replace T3 in MCT8-dependent tissues and restore normal thyroid hormone activity [ 47 , 48 ]. Commonly reported adverse effects of tiratricol involve hyperhidrosis, diarrhea, irritability, anxiety, and nightmares [ 47 ]. Fig. 4 Comparison of the structures of tiratricol, a dual thyroid hormone receptor TRα and TRβ agonist, and the human thyroid hormones 3,3’,5-triiodothyronine (T3; INN liothyronine) and L-thyroxine (T4; INN levothyroxine). T3 is a 5’-deiodinized form of T4 (3,3‘,5,5’-tetraiodo-L-thyronine). Tiratricol (3,3’,5-triiodothyroacetic acid) is a derivative (and metabolite) of T3 [ 48 ]. INN, international nonproprietary name

New multi-target drugs in 2025 – evaluation

In Germany, newly introduced drugs are subjected to at least two systems of evaluation. The first evaluation system is described in the Pharmazeutische Zeitung , a weekly appearing journal for pharmacists, in which the degree of innovation is given in terms of me-too preparation, step innovation, and disruptive innovation (taken from Gensthaler et al., 2026 [ 90 ]). Table 2 provides rating for each of the 11 compounds. Drugs were rated as step or disruptive innovations with three exceptions only. The second type of evaluation is provided by the Joint Federal Committee (Gemeinsamer Bundesausschuss) consisting of representatives of physicians, dentists, hospitals, and health insurance providers. In accordance with the German Social Code, Book Five (SGB V), section 35a, after six months they check whether a newly introduced drug has an advantage over the standard therapy. When an additional benefit cannot be demonstrated, the annual treatment costs of the new drug must not exceed those of the appropriate comparator [ 91 ]. This procedure is more rigorous than that of the EMA, which postulates the therapeutic effect and safety of the new drug only. A considerable additional benefit exists for (one indication of) inavolisib (Table 2 ). For mirdametinib, vorasidenib, and tiratricol, an additional benefit was also demonstrated, although its magnitude could not be quantified (Table 2 ). Notably, for orphan drugs the additional medical benefit is considered to be proven through the grant of the marketing authorization.

Post-marketing surveillance of multi-target drugs authorized by EMA in 2022 to 2024: safety verification

Our search in the PubMed database revealed that post-registration safety evaluation studies were available for 19 out of the 27 compounds marketed in Germany in 2022–2024 [ 12 , 13 ] and still available on the EU market (Table 3 ). Duvelisib (indicated for chronic lymphatic leukemia or follicular lymphoma [ 12 ]) was withdrawn in EU in February 2026 upon the request of the authorization holder due to commercial reasons [ 92 ]. The majority of real-world safety data in those studies was derived from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), which, although primarily reflecting the United States population, provides valuable early pharmacovigilance insights also for the use of these drugs in Europe. Table 3 Summary of post-marketing pharmacovigilance studies regarding multi-target-directed ligands introduced in Germany in years 2022–2024 INN (brand name) Short description Indications 1 Post-marketing data Comparison to safety profile of other drugs Sex/Age analysis Main ADRs; new signals Advantage of polypharmacology in terms of drug safety Clinical recommendations References Trastuzumab deruxtecan (Enhertu ® ) antibody-drug conjugate unresectable or metastatic HER2-positive (or HR-positive, HER2-low or HER2-ultralow) breast cancer; advanced NSCLC with activating HER2 mutation; advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma 5 studies (including 3 based on FAERS 2 and 1 on JADER 3 ) yes partial 4 interstitial lung disease, pulmonary embolism, musculoskeletal, infection-related, and GI ADRs, left ventricular dysfunction n/e dose adjustment, interstitial lung disease monitoring [ 93 – 98 ] Enfortumab vedotin (Padcev ® ) antibody-drug conjugate unresectable or metastatic urothelial cancer (as monotherapy or in combination with pembrolizumab) 3 studies (FAERS) yes (other ADCs) yes (higher cardiovascular risk in males) focus on peripheral neuropathy, skin reactions [ 99 , 100 ], and cardiovascular symptoms [ 93 ]; new: SJS/TEN-like reactions (fatal skin toxicity); retroperitoneal fibrosis n/e early dermatologic and cardiovascular monitoring [ 93 , 99 – 101 ] Amivantamab (Rybrevant ® ) bispecific antibody advanced NSCLC with EGFR mutations (in combinations or as monotherapy) 4 studies (FAERS) no partial; mortality ↑ in older males with pneumonitis or pneumonia infusion-related reaction, rash, acneiform dermatitis, paronychia, venous thrombosis, abnormal blood pressure, hypokalemia n/e strict monitoring, including dermatologic and cardiovascular ADRs (high mortality!), dose adjustment [ 102 – 106 ] Teclistamab (Tecvayli ® ), Talquetamab (Talvey ® ), Elranatamab (Elrexfio ® ) bispecific antibodies relapsed and refractory MM (after at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody in patients who have demonstrated disease progression on the last therapy) 2 studies (FAERS) yes (other T-cell engagers, including glofitamab, epcoritamab, mosunetuzumab, tebentafusp) no CRS and ICANS (e.g. consciousness level↓); elranatamab : eye disorders new: teclistamab : spinal cord compression, unresponsiveness to stimuli, elranatamab : hydronephrosis, syncope n/e monitoring for delayed toxicities, high vigilance [ 107 – 111 ] Glofitamab (Columvi ® ) bispecific antibody relapsed or refractory DLBCL (after at least two lines of systemic therapy) 2 studies (FAERS) yes (see teclistamab) partial (worse outcomes in older males) CRS; mantle cell lymphoma; new: hypogammaglobulinemia n/e CRS prevention, pre-treatment protocols, monitoring for early toxicities [ 107 , 112 , 113 ] Epcoritamab (Tepkinly ® ) bispecific antibody relapsed or refractory DLBCL and follicular lymphoma (after at least two lines of systemic therapy) 2 studies (FAERS) yes (see teclistamab) no CRS, ICANS, renal and urinary disorders, infections; new : hydronephrosis, PML n/e early monitoring of renal and urinary function; vigilance for CRS [ 21 , 107 , 114 ] Mosunetuzumab (Lunsumio ® ) bispecific antibody relapsed or refractory follicular lymphoma (after at least two prior systemic therapies) 1 study (FAERS) yes (see teclistamab) no CRS; new: vasogenic cerebral edema, second malignant neoplasms n/e monitoring for delayed neurologic symptoms and CRS [ 107 , 115 ] Tebentafusp (Kimmtrak ® ) bispecific fusion protein HLA-A*02:01-positive unresectable or metastatic uveal melanoma 1 study (FAERS) yes (see teclistamab) no CRS, vascular disorders, reproductive system and breast disorders n/e monitoring for vascular complications, delayed ADRs, and CRS [ 107 , 116 ] Fruquintinib (Fruzaqla ® ) kinase inhibitor metastatic colorectal cancer in patients treated previously with standard therapies (fluoropyrimidine-, oxaliplatin-, and irinotecan-based), anti-VEGF and anti-EGFR agents, who have progressed on/are intolerant to trifluridine-tipiracil or regorafenib 2 studies (FAERS) yes (other tyrosine kinases) yes (male patients more likely to develop dysphonia and myelosuppression; females - hypertension, diarrhea, nausea, and pain; elderly - more susceptible to asthenia) fatigue, hypertension, diarrhea, asthenia, dysphonia, stomatitis; neurological, renal, and cardiovascular toxicities; new : dehydration; myelosuppression, peripheral neuropathy, posterior reversible encephalopathy syndrome; intestinal and biliary obstruction; thrombotic microangiopathy (kidney) n/e early monitoring (first month of therapy) for hypertension, dehydration, neurological symptoms, renal dysfunction, and hematologic toxicity [ 117 – 119 ] Futibatinib (Lytgobi ® ) kinase inhibitor locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy 1 study (FAERS) yes (other FGFR inhibitors) limited; mortality ↑ in patients ≤ 65 hyperphosphatemia, hypercalcemia, nail toxicity, diarrhea; new: hypomagnesemia n/e lab monitoring, early toxicity management [ 120 , 121 ] Ritlecitinib (Litfulo ® ) kinase inhibitor severe alopecia areata in adults and adolescents 12 years of age and older 3 studies (FAERS) yes (other JAK inhibitors) limited; infections more common among females skin disorders, infections, hypercholesterolemia, GI ADRs, CK ↑; new: hair color changes, herpes simplex reactivation, laryngitis, diabetes mellitus, thyroid disorder n/e monitor GI symptoms and CK levels [ 122 – 125 ] Ripretinib (Qinlock ® ) kinase inhibitor advanced GI stromal tumor in patients who have received prior treatment with three or more kinase inhibitors, including imatinib 5 studies (FAERS) yes (avapritinib, imatinib, sunitinib) yes (male patients more frequently reported alopecia, tumor progression, abnormal hair texture, and fatigue; females - hyperkeratosis, and tumor-associated pain; elderly - more susceptible to ADRs) GI disorders (constipation, diarrhea), skin and subcutaneous tissue disorders (alopecia, dry skin, PPES), pruritus, muscle spasms, hypertension, appetite↓, fatigue; new: hepatic neoplasm, hepatic lesion, liver abscess; skin papillomas, melanocytic nevi, abnormal hair texture; pleural mass, electrolyte abnormalities, hypersomnia, coagulation-related bleeding n/e regular monitoring of hepatic function, dermatologic changes, blood pressure, electrolytes, coagulation parameters, and tumor-related symptoms [ 126 – 131 ] Desvenlafaxine (Desveneurax ® ) small molecule major depression 1 study (FAERS) yes (fluoxetine) yes; lower suicidality risk vs fluoxetine in the entire population and in ≤ 18 and ≥65 year old patients lower suicidality risk vs fluoxetine n/e consider in patients at high risk for suicidality [ 12 , 132 ] Tirzepatide (Mounjaro ® ) peptide type 2 diabetes mellitus in patients ≥ 10 years of age as an adjunct to diet and exercise; weight management in patients with initial BMI ≥ 30 kg/m 2 (obesity) or ≥27 kg/m 2 to < 30 kg/m 2 (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension) 16 studies (including 1 FAERS- & VigiBase 4 -based & 9 FAERS-based) yes (GLP-1 analogues, e.g., semaglutide; insulin) yes; higher frequency of GI issues, sleep disorders and medullary thyroid carcinoma ( males ) and of ketoacidosis and injection site reactions ( females ) GI issues; new: gastroesophageal reflux disease, blood glucose ↑, postmenopausal hemorrhage, menstrual disorder, sleep disorder, Wernickeʼs encephalopathy, non-arteritic anterior ischemic optic neuropathy; additional problems: injection site reactions, incorrect dose administration, off-label use yes; frequency of some ADRs of tirzepatide < semaglutide (e.g., GI issues, pancreatico-biliary disorders, acute kidney injury, suicidality, diabetic retinopathy) or even beneficial effect of tirzepatide (promotion of bone formation) gradual dose escalation, GI monitoring [ 133 – 149 ] Etrasimod (Velsipity ® ) small molecule ulcerative colitis (moderately to severely active) in patients aged 16 and older who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biological agent 2 studies (FAERS) yes (other S1P modulators, fingolimod and ozanimod) limited (male-specific hepatobiliary risk) general disorders and administration site conditions, GI, ocular, metabolic, and immune system disorders; new: drug ineffectiveness and ulcerative colitis exacerbation; headache, dizziness, fatigue, diarrhea, blurred vision yes, shorter half-life, improved safety vs other S1P modulators lymphocyte and liver monitoring [ 150 – 152 ] Sparsentan (Filspari ® ) small molecule primary immunoglobulin A nephropathy 3 studies (including 1 FAERS- & VigiBase 5 -based & 2 FAERS-based) yes (irbesartan) yes (ADRs slightly more common in males and elderly patients) hypotension, dizziness, fatigue, nausea, peripheral edema, hyperkalemia, headache, renal impairment; new : somnolence, loss of consciousness; renal pain, abnormal creatinine metabolism, fluid retention; hepatic dysfunction; ear disorders, musculoskeletal chest pain n/e regular monitoring of blood pressure, renal and hepatic function, electrolytes, and fluid retention; individualized dose adjustment and close surveillance [ 153 – 156 ] Zilucoplan (Zilbrysq ® ) peptide generalized myasthenia gravis (as add-on to standard therapy) 1 study (FAERS) yes (other new drugs used for treatment of myasthenia gravis) limited injection site reactions; new: weight gain or loss n/e continued long-term monitoring [ 157 , 158 ] The table comprises drugs for which at least one comprehensive post-approval pharmacovigilance study is available. Drugs are arranged as in Table 2 , i.e., (i) ADCs, (ii) bispecific antibodies, (iii) kinase inhibitors, and (iv) other drugs. For each drug, the indication is given; if not stated otherwise, the respective drug was approved for use in adults only; n/e, not established 1 for more details regarding indications please see respective summaries of product characteristics, EMA 2 FAERS, Food and Drug Administration Adverse Event Reporting System 3 JADER, Japanese Adverse Drug Event Report database 4 sex differences may largely reflect underlying disease epidemiology rather than true biological variability 5 VigiBase, WHO (World Health Organization) counterpart of the FAERS, aggregating reports from over 180 countries ADC(s), antibody-drug conjugate(s); ADR(s), adverse drug reaction(s); BMI, body mass index; CD38, cluster of differentiation 38; CK, creatine kinase; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; FGFR(2), fibroblast growth factor receptor (2); GI, gastrointestinal; GLP-1, glucagon-like peptide 1; HLA, human leukocyte antigen; HR, hormone receptors (estrogen and progesterone receptors); ICANS, immune effector cell-associated neurotoxicity syndrome; INN, international nonproprietary name; JAK, Janus non-receptor tyrosine kinase; MM, multiple myeloma; NSCLC, non-small cell lung cancer; PML, progressive multifocal leukoencephalopathy; PPES, palmar-plantar erythrodysesthesia syndrome; S1P, sphingosine-1-phosphate; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; VEGF, vascular endothelial growth factor; ↑, increase; ↓, decrease

To the best of our knowledge, 8 MTDLs authorized in 2022–2024 still lack comprehensive post-approval safety analyses (i.e., studies focused on a wide spectrum of ADRs, and not limited to a specific organ or system), including drugs approved for the treatment of cancer ( momelotinib [ 13 ]), primary biliary cholangitis ( elafibranor [ 13 ]), hand eczema ( delgocitinib [ 13 ]), and insomnia ( daridorexant [ 12 ]). In the case of the anti-cancer agent loncastuximab tesirine [ 13 ], only hematological ADRs were considered [ 159 ]. Similarly, in the case of another anti-cancer agent, capivasertib [ 13 ] only ADRs within the oral cavity were analyzed [ 160 ]. In both instances, new safety signals were not observed. In the case of vamorolone (indicated for the treatment of Duchenne muscular dystrophy in patients ≥ 2 years of age [ 13 ]), the analysis of the FAERS database was performed in the context of drug-induced urinary incontinence only; pediatric urinary incontinence was identified as a new signal [ 161 ]. The post-marketing safety of faricimab (indicated for the treatment of age-related macular degeneration [ 12 ]) was assessed only in a small case-series study focusing on the eye which revealed sterile intraocular inflammation as a so far unknown ADR [ 162 ].

The post-marketing safety analysis of the anti-HER2 (see glossary in Table 1 ) ADC trastuzumab deruxtecan showed high rates of grade ≥ 3 adverse events (Table 1 ) in real-world settings, particularly interstitial lung disease, necessitating dose adjustments and careful monitoring [ 93 – 95 ]. In the case of another ADC, enfortumab vedotin , indicated for advanced urothelial carcinoma [ 12 ], the studies focused on dermatologic and cardiovascular toxicity [ 93 , 99 , 100 ] and revealed severe cutaneous reactions such as Stevens-Johnson syndrome (SJS) as new signals (Table 3 ).

The bispecific antibody amivantamab was approved for the treatment of some forms of advanced NSCLC [ 12 ]. Its use has been associated with several serious ADRs, such as pneumonitis, pneumonia, and dermatological complications. Safety concerns are particularly pronounced in older male patients, who appear to be at an increased risk of pulmonary complications. In addition, amivantamab has raised concerns regarding cardiovascular safety, with cardiovascular adverse events accounting for a substantial proportion of fatal outcomes (16.3%). Major adverse cardiovascular events were associated with particularly poor prognosis, with mortality reaching up to 60% in reported cases [ 102 – 105 ].

Another six bispecific antibodies ( teclistamab , talquetamab , elranatamab , glofitamab , epcoritamab [ 13 ], and mosunetuzumab [ 12 ]) and a fusion protein ( tebentafusp [ 12 ]) are also anti-tumor drugs (for indications, see Table 3 ). They share a similar mechanism of action involving simultaneous binding to a tumor antigen and to CD3 on cytotoxic T cells, which results in the activation of the latter and subsequent tumor cell lysis. T-cell activation is associated with the release of proinflammatory cytokines, explaining why T-cell engagers can elicit a CRS and an immune effector cell-associated neurotoxicity syndrome (ICANS; for glossary, see Table 1 ). The ADRs of the seven drugs were compared to each other in a FAERS-based study [ 107 ] and many common properties but also marked differences were found (Table 3 ). Moreover, their safety profiles vary, according to target antigen and pharmacokinetic properties. Agents directed against BCMA (teclistamab, elranatamab) and G protein-coupled receptor class C group 5 member D (GPRC5D) (talquetamab) are more often associated with delayed-onset toxicities, including CRS, ICANS, and organ-specific signals such as ocular, skin, and, in some cases, novel malignancy or renal-related events. CD20-directed bispecific antibodies (glofitamab, epcoritamab, mosunetuzumab) show more heterogeneous profiles, with glofitamab demonstrating earlier toxicity onset due to a shorter half-life, while epcoritamab and mosunetuzumab are associated with delayed inflammatory and multi-organ immune-related ADRs. Tebentafusp, not targeting BCMA, GPRC5D or CD20, shows an early onset toxicity profile dominated by vascular events with fewer infectious complications [ 107 ]. Concerning the severity of ADRs, approximately 50% of the reports for epcoritamab, elranatamab, and mosunetuzumab involved hospitalization, indicating the potential seriousness of these events. Conversely, talquetamab demonstrated relatively lower hospitalization and mortality rates, suggesting a more favorable safety profile [ 107 ]. New safety signals were detected for glofitamab (hypogammaglobulinemia), epcoritamab (hydronephrosis, progressive multifocal leukoencephalopathy (PML), see glossary in Table 1 ), mosunetuzumab (vasogenic cerebral edema, second malignant neoplasms), and tebentafusp (vascular, breast and reproductive system disorders) [ 107 ].

Four small molecules targeting different sets of kinases were considered as well. FAERS-based studies for fruquintinib , approved for the treatment of metastatic colorectal cancer [ 13 ], revealed new hematological, neurological, GI, renal, and cardiovascular ADRs (Table 3 ). Post-marketing data for futibatinib (indicated for the treatment of advanced bile duct cancer [ 13 ]) revealed new safety concerns such as hypomagnesemia and a higher mortality signal in younger patients [ 120 ] (Table 3 ). The increased mortality was not shared by another two FGFR inhibitors, erdafitinib and pemigatinib [ 120 ]. For ritlecitinib , approved for the treatment of severe alopecia areata [ 13 ], FAERS data revealed drug-specific safety signals, including GI events and elevated creatine kinase, with early onset after treatment initiation, supporting the need for monitoring; new signals were also identified (Table 3 ). Ripretinib , indicated for the treatment of advanced GI stromal tumors [ 12 ], frequently led to disorders of the GI tract and of the skin and subcutaneous tissue. As novel safety signals abnormalities of the liver, skin, and hematologic system were identified [ 126 – 130 ] (Table 3 ).

Desvenlafaxine is an antidepressant that simultaneously inhibits the neuronal serotonin and noradrenaline transporters [ 12 ]. With respect to the treatment of children and adolescents, antidepressants, except for fluoxetine, do not offer a clear advantage over placebo, and some antidepressants might increase the risk of suicidality (suicidal ideation, suicide attempt, completed suicide) [ 163 ]. If one considers antidepressant effectiveness plus effect on suicidality, fluoxetine is relatively favorable in this age group. Fluoxetine (approved for antidepressant treatment in children and adolescents both by the FDA and the EMA) served as the comparator in a FAERS analysis in which desvenlafaxine and another 37 antidepressants as well as lithium were considered [ 132 ]. Only desvenlafaxine and vilazodone were able to outperform fluoxetine with a reduced risk of reporting suicidality in the entire study population; desvenlafaxine was superior to fluoxetine also in the group of children and adolescents (Table 3 ).

Tirzepatide , approved for type 2 diabetes and weight management [ 13 ], is one of the most extensively characterized agents in the post-marketing setting, supported by multiple pharmacovigilance real-world studies (Table 3 ). Post-marketing data confirm the profile of ADRs and have further expanded their list [ 133 – 135 ]. A notable real-world issue with tirzepatide is the increasing frequency of dosing errors, underscoring the importance of patient education and structured therapeutic support [ 136 ]. Real-world pharmacovigilance analyses have demonstrated lower reporting odds for heart failure with tirzepatide, without significant signals for ischemic or arrhythmic events in healthcare professional reports [ 137 ]. These findings are especially relevant given the growing interest in tirzepatide for heart failure with preserved ejection fraction [ 164 ].

Comparative analyses suggest a favorable safety profile of tirzepatide in comparison to semaglutide. This is remarkable since tirzepatide (an analogue of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) causes an even higher weight loss (by ~ 5%) than semaglutide (GLP-1 analogue only) [ 165 ]. (i) The frequency of many ADRs is similar for tirzepatide vs semaglutide (e.g. [ 133 , 138 ]). (ii) Lower reporting rates of acute kidney injury, and no significant signal of suicidality were published for tirzepatide when compared to semaglutide [ 139 – 141 ]. (iii) In marked contrast to semaglutide, tirzepatide has even a beneficial effect on bone (suppression of bone resorption and increase in bone formation) [ 142 ].

Among drugs indicated for the treatment of diseases of the immune system, etrasimod , a sphingosine-1-phosphate (S1P) modulator, is indicated for the treatment of ulcerative colitis [ 13 ] (Table 3 ). This drug exhibited a favorable lymphocyte safety signal relative to other S1P modulators, alongside a shorter half-life and reduced risk of prolonged immunosuppression; hepatobiliary adverse events were noted predominantly in male patients. Interestingly enough, the drug frequently proved to be ineffective or even aggravated ulcerative colitis [ 150 , 151 ]. In the case of sparsentan , indicated for immunoglobulin A nephropathy [ 13 ], new safety signals comprise neurological, renal, and hepatic ADRs [ 153 – 155 ] (Table 3 ). Zilucoplan was approved for the treatment of myasthenia gravis [ 13 ]. Post-marketing safety analysis confirmed that injection site reactions are common ADRs (probably due to the subcutaneous mode of administration) and revealed weight gain or, even more often, its loss as new signals (Table 3 [ 157 ]). Zilucoplan is just one of 5 new drugs for the treatment of myasthenia gravis (see glossary, Table 1 ), and serious reports of events were 82%, as compared to ravulizumab (33%), eculizumab (38%), rozanolixizumab (78%) and efgartigimod (93%) [ 157 ].

Across studies, consideration of demographic variables such as sex and age was inconsistent. While some analyses identified clinically relevant differences, including sex-specific ADRs and age-related variability in outcomes, the lack of systematic stratification represents a major limitation. Additional constraints include reliance on FAERS data, underreporting, reporting bias, reporting by health professionals vs patients, and the absence of denominator data, precluding incidence estimation and causal inference.

Practical clinical actions proposed in the literature include gradual dose escalation, routine laboratory monitoring, early recognition of ADRs, and structured patient education (Table 3 ). These strategies underscore the importance of multidisciplinary collaboration in post-marketing pharmacovigilance, involving physicians, nurses, clinical pharmacists, and other healthcare professionals working closely with patients. Such integrated cooperation may help to reduce the burden on healthcare systems by supporting adverse event reporting, maintaining real-world data registries, facilitating early signal detection, and improving treatment adherence and patient awareness of potential therapy-related risks [ 166 ].

Conclusions

Polypharmacology is an emerging paradigm in drug design, development, and clinical implementation, which involves MTDLs, able to interact with multiple molecular targets simultaneously, as a more optimal alternative to single-target-based therapy, especially in the context of chronic multifactorial diseases. Among the 38 substances approved by the EMA and introduced in Germany in 2025, 11 were classified as MTDLs, i.e., antibody-drug conjugates, bispecific antibodies, and small molecules. There is minimal year-to-year fluctuation in the number of polypharmacological drugs brought to the market (11 substances approved in 2024, 7 in 2023, and 10 in 2022 (Ryszkiewicz et al., 2023 [ 12 ], 2025 [ 13 ]) and their primary indication, as most of them are tailored for cancer treatment. Eight of the 11 drugs approved by the EMA in 2025 were rated as step or disruptive innovations according to Pharmazeutische Zeitung , a German journal for pharmacists. Another rating in Germany (by Joint Federal Committee) revealed a considerable additional benefit of inavolisib over the standard therapy regarding PIK3CA -mutated breast cancer in patients not treated previously with a CDK4/6 inhibitor, and a non-quantifiable benefit in the case of mirdametinib, vorasidenib, and tiratricol.

Post-marketing pharmacovigilance studies remain essential for optimizing the safe use of newly authorized therapies, including those with polypharmacological mechanisms of action. Despite some methodological weaknesses, such studies are particularly important since they reflect real-world conditions and encompass far higher numbers of treated persons than in clinical phases 1–3. For such studies, the real-world databases such as FAERS are of utmost importance. As expected, ADRs listed in the EMA summaries of product characteristics occurred, but also new safety signals, including the potentially fatal SJS and PML, were identified. It is intriguing that the dual GLP-1 and GIP analogue not only reduces weight more strongly than a selective GLP-1 analogue, but also has a more favorable safety profile (e.g., lower frequency of acute kidney injury and no significant suicidality signal).

Abbreviations

2-hydroxyglutarate

Antibody-drug conjugate(s)

Antibody-dependent cellular cytotoxicity

Antibody-dependent cellular phagocytosis

Adverse drug reaction(s)

Artificial intelligence

Protein kinase B

Anaplastic lymphoma kinase

Alanine aminotransferase

Aspartate aminotransferase

Anatomical therapeutical chemical classification

Adenosine triphosphate

B-cell maturation antigen

Body mass index

Cluster of differentiation 3, 20, 38

Cyclin-dependent kinase 4/6

Calcitonin gene-related peptide

Creatine kinase

Clustered regularly interspaced short palindromic repeats

Cytokine release syndrome

Diffuse large B-cell lymphoma

Deruxtecan

Epidermal growth factor receptor

European Medicines Agency

Extracellular signal-regulated kinase

European Union

Food and Drug Administration Adverse Event Reporting System

Fragment crystallizable region of an antibody

Food and Drug Administration

Fibroblast growth factor

Fibroblast growth factor receptor 2, 3

Gamma-glutamyltransferase

Gastrointestinal

Glucose-dependent insulinotropic polypeptide

Glucagon-like peptide-1

G protein-coupled receptor class C group 5 member D

Human epidermal growth factor receptor 2

Receptor tyrosine kinase within the erb-b2 family

Human leukocyte antigen

Human papillomavirus

Hormone receptors (estrogen and progesterone receptors)

Immune effector cell-associated neurotoxicity syndrome

Isocitrate dehydrogenase 1, 2

Immunoglobulin G1

Immunoglobulin G4

Interleukin 6

International nonproprietary name

Janus non-receptor tyrosine kinase

Human polyomavirus 2

Monocarboxylate transporter 8

Mitogen-activated protein kinase 1, 2

Major histocompatibility complex

Multiple myeloma

Monomethyl auristatin E

Magnetic resonance imaging

Multi-target-directed ligand(s)

Mammalian target of rapamycin serine/threonine protein kinase

Neurofibromin 1 gene

Non-small cell lung cancer

Neurotrophic receptor tyrosine kinase

p -aminobenzoic acid

Programmed death receptor 1

Programmed death receptor 1 ligand 1

Phosphatidylinositol-3-kinase

Phosphatidylinositol-4, 5-bisphosphate-3-kinase catalytic subunit alpha gene /protein

Progressive multifocal leukoencephalopathy

Palmar-plantar erythrodysesthesia syndrome

Rapidly accelerated fibrosarcoma serine/threonine protein kinase

Ras (rat sarcoma virus) GTPase

ROS proto-oncogene 1 receptor tyrosine kinase

Sphingosine-1-phosphate

German Social Code Book Five

Stevens-Johnson syndrome

Monocarboxylate transporter 8 gene

Triiodothyronine, liothyronine

L-thyroxine, levothyroxine

Toxic epidermal necrolysis

Tissue factor

Tyrosine kinase inhibitor(s)

Tropomyosin receptor tyrosine kinase

Tropomyosin receptor tyrosine kinase A, B, C

Trophoblast cell surface antigen 2

Thyroid hormone receptors α, β

Vascular endothelial growth factor

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author contributions

Piotr Ryszkiewicz (PR): conceptualization, data curation, funding acquisition, methodology, project administration, resources, software, visualization, writing – original draft, writing – review and editing, Marta Baranowska-Kuczko (MB-K): data curation, writing – original draft, writing – review and editing, Barbara Malinowska (BM): writing – review and editing

Eberhard Schlicker (ES): supervision, writing – review and editing

Funding

The study was supported by the Medical University of Białystok, Poland (B.SUB.26.129).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethical approval

Not applicable.

Disclosure of using artificial intelligence (AI) in the writing process

No AI or AI-assisted technologies were used in the preparation of this manuscript.

Competing interests

The authors declare no competing interests.

References

1. Stefan SM Rafehi M Medicinal polypharmacology—a scientific glossary of terminology and concepts Front Pharmacol 2024 15 1419110 10.3389/fphar.2024.1419110 39092220 PMC11292611 Stefan SM, Rafehi M. Medicinal polypharmacology—a scientific glossary of terminology and concepts. Front Pharmacol. 2024;15:1419110. 10.3389/fphar.2024.1419110. 39092220 10.3389/fphar.2024.1419110 PMC11292611

2. Rafehi M Moller M Ismail Al-Khalil W Stefan SM Medicinal polypharmacology in the clinic – translating the polypharmacolome into therapeutic benefit Pharm Res 2024 41 3 411 17 10.1007/s11095-024-03656-8 38366233 PMC10927880 Rafehi M, Moller M, Ismail Al-Khalil W, Stefan SM. Medicinal polypharmacology in the clinic – translating the polypharmacolome into therapeutic benefit. Pharm Res. 2024;41(3):411–17. 10.1007/s11095-024-03656-8. 38366233 10.1007/s11095-024-03656-8 PMC10927880

3. Shaaban AE Ali AR Ayyad SN Badria FA Multi-target directed ligands inspired natural products as an effective approach for the treatment of complex chronic health disorders Bioorg Chem 2025 154 108075 10.1016/j.bioorg.2024.108075 39708551 Shaaban AE, Ali AR, Ayyad SN, Badria FA. Multi-target directed ligands inspired natural products as an effective approach for the treatment of complex chronic health disorders. Bioorg Chem. 2025;154:108075. 10.1016/j.bioorg.2024.108075. 39708551 10.1016/j.bioorg.2024.108075

4. El-Sagheir AMK Wenzel M Yli-Kauhaluoma J Fluoroquinolones as versatile scaffolds: potential for targeting classical and novel mechanisms to combat antibacterial resistance Eur J Pharm Sci 2025 214 107247 10.1016/j.ejps.2025.107247 40882713 El-Sagheir AMK, Wenzel M, Yli-Kauhaluoma J. Fluoroquinolones as versatile scaffolds: potential for targeting classical and novel mechanisms to combat antibacterial resistance. Eur J Pharm Sci. 2025;214:107247. 10.1016/j.ejps.2025.107247. 40882713 10.1016/j.ejps.2025.107247

5. Ge M Chen XY Huang P Fleishman JS Yang DH Wu ZX Understanding and overcoming multidrug resistance in cancer Nat Rev Clin Oncol 2025 22 10 760 80 10.1038/s41571-025-01059-1 40731166 Ge M, Chen XY, Huang P, Fleishman JS, Yang DH, Wu ZX, et al. Understanding and overcoming multidrug resistance in cancer. Nat Rev Clin Oncol. 2025;22(10):760–80. 10.1038/s41571-025-01059-1. 40731166 10.1038/s41571-025-01059-1

6. Doostmohammadi A Jooya H Ghorbanian K Gohari S Dadashpour M Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents Cell Commun Signal 2024 22 1 228 10.1186/s12964-024-01607-9 38622735 PMC11020265 Doostmohammadi A, Jooya H, Ghorbanian K, Gohari S, Dadashpour M. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents. Cell Commun Signal. 2024;22(1):228. 10.1186/s12964-024-01607-9. 38622735 10.1186/s12964-024-01607-9 PMC11020265

7. Abdelsayed M AI-Driven polypharmacology in Small-molecule Drug discovery IJMS 2025 26 14 6996 10.3390/ijms26146996 40725243 PMC12295758 Abdelsayed M. AI-driven polypharmacology in small-molecule drug discovery. IJMS. 2025;26(14):6996. 10.3390/ijms26146996. 40725243 10.3390/ijms26146996 PMC12295758

8. Joshi CP Baldi A Kumar N Pradhan J Harnessing network pharmacology in drug discovery: an integrated approach Naunyn-Schmiedeberg’s Arch Pharmacol 2025 398 5 4689 703 10.1007/s00210-024-03625-3 39621088 Joshi CP, Baldi A, Kumar N, Pradhan J. Harnessing network pharmacology in drug discovery: an integrated approach. Naunyn-Schmiedeberg’s Arch Pharmacol. 2025;398(5):4689–703. 10.1007/s00210-024-03625-3. 39621088 10.1007/s00210-024-03625-3

9. Singh S, Kumar R, Payra S, Singh SK. Artificial intelligence and machine learning in pharmacological research: bridging the gap between data and drug discovery. Cureus. 2023;15(8):e44359. 10.7759/cureus.44359. 10.7759/cureus.44359 PMC10539991 37779744

10. Kang SI Shin JH Wu BM Choi HS Deep generative AI for multi-target Therapeutic design: toward self-improving Drug discovery framework IJMS 2025 26 23 11443 10.3390/ijms262311443 41373598 PMC12691712 Kang SI, Shin JH, Wu BM, Choi HS. Deep generative AI for multi-target therapeutic design: toward self-improving drug discovery framework. IJMS. 2025;26(23):11443. 10.3390/ijms262311443. 41373598 10.3390/ijms262311443 PMC12691712

11. Brauer NR Kempen AL Hernandez D Sintim HO Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors Eur J Med Chem 2024 275 116540 10.1016/j.ejmech.2024.116540 38852338 PMC11243610 Brauer NR, Kempen AL, Hernandez D, Sintim HO. Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors. Eur J Med Chem. 2024;275:116540. 10.1016/j.ejmech.2024.116540. 38852338 10.1016/j.ejmech.2024.116540 PMC11243610

12. Ryszkiewicz P Malinowska B Schlicker E Polypharmacology: promises and new drugs in 2022 Pharmacol Rep 2023 75 4 755 70 10.1007/s43440-023-00501-4 37278927 PMC10243259 Ryszkiewicz P, Malinowska B, Schlicker E. Polypharmacology: promises and new drugs in 2022. Pharmacol Rep. 2023;75(4):755–70. 10.1007/s43440-023-00501-4. 37278927 10.1007/s43440-023-00501-4 PMC10243259

13. Ryszkiewicz P Malinowska B Schlicker E Polypharmacology: new drugs in 2023–2024 Pharmacol Rep 2025 77 3 543 60 10.1007/s43440-025-00715-8 40095348 PMC12066383 Ryszkiewicz P, Malinowska B, Schlicker E. Polypharmacology: new drugs in 2023–2024. Pharmacol Rep. 2025;77(3):543–60. 10.1007/s43440-025-00715-8. 40095348 10.1007/s43440-025-00715-8 PMC12066383

14. Kabir A Muth A Polypharmacology: the science of multi-targeting molecules Pharmacological Res 2022 176 106055 10.1016/j.phrs.2021.106055 34990865 Kabir A, Muth A. Polypharmacology: the science of multi-targeting molecules. Pharmacol Res. 2022;176:106055. 10.1016/j.phrs.2021.106055. 10.1016/j.phrs.2021.106055 34990865

15. Crisafulli S Khan Z Karatas Y Tuccori M Trifiro G An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting Expert Opin Drug Saf 2023 22 5 373 80 10.1080/14740338.2023.2219892 37243676 Crisafulli S, Khan Z, Karatas Y, Tuccori M, Trifiro G. An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting. Expert Opin Drug Saf. 2023;22(5):373–80. 10.1080/14740338.2023.2219892. 37243676 10.1080/14740338.2023.2219892

16. Michaeli DT Michaeli T Albers S Boch T Michaeli JC Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy Eur J Health Econ 2024 25 6 979 97 10.1007/s10198-023-01639-x 37962724 PMC11283430 Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2024;25(6):979–97. 10.1007/s10198-023-01639-x. 37962724 10.1007/s10198-023-01639-x PMC11283430

17. Leveque D The importance and utility of post market drug safety monitoring in cancer therapy Expert Opin Drug Saf 2026 25 5 823 35 10.1080/14740338.2025.2575099 41098057 Leveque D. The importance and utility of post market drug safety monitoring in cancer therapy. Expert Opin Drug Saf. 2026;25(5):823–35. 10.1080/14740338.2025.2575099. 41098057 10.1080/14740338.2025.2575099

18. National comprehensive cancer network: NCCN guidelines for Patients ® “invasive breast cancer”. https://www.nccn.org . Accessed 18 May 2026.

19. Giles HV Kishore B Bispecific antibodies: strategies available to optimize their safe delivery in patients with multiple myeloma Antibodies (Basel) 2026 15 1 5 10.3390/antib15010005 41562778 PMC12821579 Giles HV, Kishore B. Bispecific antibodies: strategies available to optimize their safe delivery in patients with multiple myeloma. Antibodies (Basel). 2026;15(1):5. 10.3390/antib15010005. 41562778 10.3390/antib15010005 PMC12821579

20. Crisafulli S Boccanegra B Carollo M Bottani E Mantuano P Trifiro G Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future CNS Drugs 2024 38 1 15 32 10.1007/s40263-023-01059-8 38212553 Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifiro G, et al. Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future. CNS Drugs. 2024;38(1):15–32. 10.1007/s40263-023-01059-8. 38212553 10.1007/s40263-023-01059-8

21. Lin X Qin N He B Chen J Zhang Y Wang H Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS Front Immunol 2026 16 1707211 10.3389/fimmu.2025.1707211 41550941 PMC12807927 Lin X, Qin N, He B, Chen J, Zhang Y, Wang H, et al. Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS. Front Immunol. 2026;16:1707211. 10.3389/fimmu.2025.1707211. 41550941 10.3389/fimmu.2025.1707211 PMC12807927

22. U.S. Department of Health and Human Services: common terminology criteria for adverse events (CTCAE) v6.0 (MedDRA 28.0). https://www.hhs.gov . Accessed 18 May 2026.

23. Singh E Bisserier M Experimental animal models and patient-derived platforms to bridge preclinical discovery and translational therapeutics in pulmonary arterial hypertension J Transl Med 2025 23 1 665 10.1186/s12967-025-06709-7 40528193 PMC12172319 Singh E, Bisserier M. Experimental animal models and patient-derived platforms to bridge preclinical discovery and translational therapeutics in pulmonary arterial hypertension. J Transl Med. 2025;23(1):665. 10.1186/s12967-025-06709-7. 40528193 10.1186/s12967-025-06709-7 PMC12172319

24. Warner J Prada Jardim A Albera C Artificial intelligence: applications in Pharmacovigilance signal management Pharm Med 2025 39 3 183 98 10.1007/s40290-025-00561-2 PMC12126317 40257538 Warner J, Prada Jardim A, Albera C. Artificial intelligence: applications in pharmacovigilance signal management. Pharm Med. 2025;39(3):183–98. 10.1007/s40290-025-00561-2. 10.1007/s40290-025-00561-2 PMC12126317 40257538

25. Manen-Freixa L Antolin AA Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery Expert Opin Drug Discov 2024 19 9 1043 69 10.1080/17460441.2024.2376643 39004919 Manen-Freixa L, Antolin AA. Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery. Expert Opin Drug Discov. 2024;19(9):1043–69. 10.1080/17460441.2024.2376643. 39004919 10.1080/17460441.2024.2376643

26. Verband Forschender Arzneimittelhersteller e.V.: Innovationsbilanz 2025. Innovation report 2025. 2025. https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025 . Accessed 15 Apr 2026.

27. Pharmazeutische Zeitung: Arzneistoffe. Jahr 2025 [Drugs. Year 2025]. 2025. https://www.pharmazeutische-zeitung.de/arzneistoff-jahrgang/jahr/2025/ . Accessed 22 May 2026.

28. Blair HA Datopotamab Deruxtecan: first approval Drugs 2025 85 7 965 75 10.1007/s40265-025-02185-x 40323341 Blair HA. Datopotamab deruxtecan: first approval. Drugs. 2025;85(7):965–75. 10.1007/s40265-025-02185-x. 40323341 10.1007/s40265-025-02185-x

29. European Medicines Agency: Datroway ® (datopotamab deruxtecan) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/datroway-epar-product-information_en.pdf . Accessed 25 May 2026.

30. Markham A Tisotumab Vedotin: first approval Drugs 2021 81 18 2141 47 10.1007/s40265-021-01633-8 34748188 Markham A. Tisotumab vedotin: first approval. Drugs. 2021;81(18):2141–47. 10.1007/s40265-021-01633-8. 34748188 10.1007/s40265-021-01633-8

31. European Medicines Agency: Tivdak ® (tisotumab vedotin) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/tivdak-epar-product-information_en.pdf . Accessed 25 May 2026.

32. Lee A Linvoseltamab: first approval Drugs 2025 85 10 1329 33 10.1007/s40265-025-02207-8 40880034 Lee A. Linvoseltamab: first approval. Drugs. 2025;85(10):1329–33. 10.1007/s40265-025-02207-8. 40880034 10.1007/s40265-025-02207-8

33. European Medicines Agency: Lynozyfic ® (linvoseltamab) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/lynozyfic-epar-product-information_en.pdf . Accessed 25 May 2026.

34. Minson AG Dickinson MJ New bispecific antibodies in diffuse large B-cell lymphoma Haematologica 2025 110 7 1483 99 10.3324/haematol.2024.285343 39911111 PMC12208169 Minson AG, Dickinson MJ. New bispecific antibodies in diffuse large B-cell lymphoma. Haematologica. 2025;110(7):1483–99. 10.3324/haematol.2024.285343. 39911111 10.3324/haematol.2024.285343 PMC12208169

35. European Medicines Agency: Ordspono ® (odronextamab) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/ordspono-epar-product-information_en.pdf . Accessed 25 May 2026.

36. European Medicines Agency: Augtyro ® (repotrectinib) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/augtyro-epar-product-information_en.pdf . Accessed 25 May 2026.

37. Dhillon S Repotrectinib: first approval Drugs 2024 84 2 239 46 10.1007/s40265-023-01990-6 38279972 Dhillon S. Repotrectinib: first approval. Drugs. 2024;84(2):239–46. 10.1007/s40265-023-01990-6. 38279972 10.1007/s40265-023-01990-6

38. European Medicines Agency: Balversa ® (erdafitinib) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf . Accessed 25 May 2026.

39. European Medicines Agency: Ezmekly ® (mirdametinib) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/ezmekly-epar-product-information_en.pdf . Accessed 25 May 2026.

40. Hoy SM Mirdametinib: First Approval Drugs 2025 85 7 977 84 10.1007/s40265-025-02190-0 40419758 PMC12234624 Hoy SM. Mirdametinib: first approval. Drugs. 2025;85(7):977–84. 10.1007/s40265-025-02190-0. 40419758 10.1007/s40265-025-02190-0 PMC12234624

41. Blair HA Inavolisib: first approval Drugs 2025 85 2 271 78 10.1007/s40265-024-02136-y 39873916 Blair HA. Inavolisib: first approval. Drugs. 2025;85(2):271–78. 10.1007/s40265-024-02136-y. 39873916 10.1007/s40265-024-02136-y

42. European Medicines Agency: Itovebi ® (inavolisib) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/itovebi-epar-product-information_en.pdf . Accessed 25 May 2026.

43. European Medicines Agency: Voranigo ® (vorasidenib) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/voranigo-epar-product-information_en.pdf . Accessed 25 May 2026.

44. Lamb YN Vorasidenib: first approval Drugs 2024 84 10 1325 31 10.1007/s40265-024-02097-2 39375303 PMC11628568 Lamb YN. Vorasidenib: First approval. Drugs. 2024;84(10):1325–31. 10.1007/s40265-024-02097-2. 39375303 10.1007/s40265-024-02097-2 PMC11628568

45. Boinpally R, Shebley M, Trugman JM. Atogepant: mechanism of action, clinical and translational science. Clin Transl Sci. 2024;17(1):e13707. 10.1111/cts.13707. 10.1111/cts.13707 PMC10777605 38266063

46. European Medicines Agency: Aquipta ® (atogepant) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/aquipta-epar-product-information_en.pdf . Accessed 25 May 2026.

47. European Medicines Agency: Emcitate ® (tiratricol) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/emcitate-epar-product-information_en.pdf . Accessed 25 May 2026.

48. Lamb YN Tiratricol: first approval Drugs 2025 85 8 1059 65 10.1007/s40265-025-02197-7 40549098 Lamb YN. Tiratricol: first approval. Drugs. 2025;85(8):1059–65. 10.1007/s40265-025-02197-7. 40549098 10.1007/s40265-025-02197-7

49. Xiong X Zheng LW Ding Y Chen YF Cai YW Wang LP Breast cancer: pathogenesis and treatments Sig Transduct Target Ther 2025 10 1 49 10.1038/s41392-024-02108-4 PMC11836418 39966355 Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Sig Transduct Target Ther. 2025;10(1):49. 10.1038/s41392-024-02108-4. 10.1038/s41392-024-02108-4 PMC11836418 39966355

50. Riaz F, Gruber JJ, Telli ML. New treatment approaches for triple-negative breast cancer. Am Soc Clin Oncol Educ Book. 2025;45(3):e481154. 10.1200/EDBK-25-481154. 10.1200/EDBK-25-481154 40460322

51. Li X Liu J Meng Y Li J Zhao J Liu D Frontiers in antibody–drug conjugates: mechanisms, design innovations, and clinical applications in targeted cancer therapy Pharmaceuticals (Basel) 2026 19 2 324 10.3390/ph19020324 41754865 PMC12943913 Li X, Liu J, Meng Y, Li J, Zhao J, Liu D, et al. Frontiers in antibody–drug conjugates: mechanisms, design innovations, and clinical applications in targeted cancer therapy. Pharmaceuticals (Basel). 2026;19(2):324. 10.3390/ph19020324. 41754865 10.3390/ph19020324 PMC12943913

52. Alda MI Grinda T Pistilli B Integrating antibody-drug conjugates into the management of early breast cancer Cancer Treat Rev 2026 144 103096 10.1016/j.ctrv.2026.103096 41653497 Alda MI, Grinda T, Pistilli B. Integrating antibody-drug conjugates into the management of early breast cancer. Cancer Treat Rev. 2026;144:103096. 10.1016/j.ctrv.2026.103096. 41653497 10.1016/j.ctrv.2026.103096

53. Tong Y Fan X Liu H Liang T Advances in trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions Front. Immunol 2024 15 1495675 10.3389/fimmu.2024.1495675 39555080 PMC11563829 Tong Y, Fan X, Liu H, Liang T. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions. Front. Immunol. 2024;15:1495675. 10.3389/fimmu.2024.1495675. 39555080 10.3389/fimmu.2024.1495675 PMC11563829

54. Michaleas S Moreno Oliver A Mueller-Berghaus J Sarac SB van der Elst ME Muller-Egert S The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer ESMO Open 2022 7 3 100497 10.1016/j.esmoop.2022.100497 35642987 PMC9149193 Michaleas S, Moreno Oliver A, Mueller-Berghaus J, Sarac SB, van der Elst ME, Muller-Egert S, et al. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer. ESMO Open. 2022;7(3):100497. 10.1016/j.esmoop.2022.100497. 35642987 10.1016/j.esmoop.2022.100497 PMC9149193

55. Di Lauro V Rizzo A Tafuro M Fina E Martinelli C Calderaio C Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives Cancer Treat Rev 2025 140 103023 10.1016/j.ctrv.2025.103023 40987130 Di Lauro V, Rizzo A, Tafuro M, Fina E, Martinelli C, Calderaio C, et al. Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives. Cancer Treat Rev. 2025;140:103023. 10.1016/j.ctrv.2025.103023. 40987130 10.1016/j.ctrv.2025.103023

56. Jouya S Shahabinia Z Mazidimoradi A Allahqoli L Salehiniya H Lee DY Cervical cancer epidemiology: global incidence, mortality, survival, risk factors, and equity in HPV screening and vaccination JCM 2026 15 3 1079 10.3390/jcm15031079 41682759 PMC12898345 Jouya S, Shahabinia Z, Mazidimoradi A, Allahqoli L, Salehiniya H, Lee DY. Cervical cancer epidemiology: global incidence, mortality, survival, risk factors, and equity in HPV screening and vaccination. JCM. 2026;15(3):1079. 10.3390/jcm15031079. 41682759 10.3390/jcm15031079 PMC12898345

57. Youssef J El Masri A Atwi M Ibrahim E Salhab Z Badawi M Molecular targets of cervical cancer and its microenvironment: advances in treatment Cancers (Basel) 2026 18 4 563 10.3390/cancers18040563 41749817 PMC12939043 Youssef J, El Masri A, Atwi M, Ibrahim E, Salhab Z, Badawi M, et al. Molecular targets of cervical cancer and its microenvironment: advances in treatment. Cancers (Basel). 2026;18(4):563. 10.3390/cancers18040563. 41749817 10.3390/cancers18040563 PMC12939043

58. Francoeur AA Monk BJ Tewari KS Treatment advances across the cervical cancer spectrum Nat Rev Clin Oncol 2025 22 3 182 99 10.1038/s41571-024-00977-w 39753753 Francoeur AA, Monk BJ, Tewari KS. Treatment advances across the cervical cancer spectrum. Nat Rev Clin Oncol. 2025;22(3):182–99. 10.1038/s41571-024-00977-w. 39753753 10.1038/s41571-024-00977-w

59. Taritsa I Fossel E Pathways of resistance: modern multiple myeloma therapies and overcoming reliance on genomic integrity IJMS 2026 27 3 1439 10.3390/ijms27031439 41683862 PMC12898762 Taritsa I, Fossel E. Pathways of resistance: modern multiple myeloma therapies and overcoming reliance on genomic integrity. IJMS. 2026;27(3):1439. 10.3390/ijms27031439. 41683862 10.3390/ijms27031439 PMC12898762

60. Zhou X Waldschmidt JM Einsele H Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies Blood Rev 2025 74 101342 10.1016/j.blre.2025.101342 41177723 Zhou X, Waldschmidt JM, Einsele H. Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies. Blood Rev. 2025;74:101342. 10.1016/j.blre.2025.101342. 41177723 10.1016/j.blre.2025.101342

61. Lopes MMC Xavier LDA Nolasco S Ribeiro SR Coutinho DF Sabino ADP Next-generation biomarkers in multiple myeloma: advancing diagnosis, risk stratification, and precision therapy beyond current guidelines Pharmaceuticals (Basel) 2026 19 2 320 10.3390/ph19020320 41754860 PMC12944283 Lopes MMC, Xavier LDA, Nolasco S, Ribeiro SR, Coutinho DF, Sabino ADP. Next-generation biomarkers in multiple myeloma: advancing diagnosis, risk stratification, and precision therapy beyond current guidelines. Pharmaceuticals (Basel). 2026;19(2):320. 10.3390/ph19020320. 41754860 10.3390/ph19020320 PMC12944283

62. Lowy JA Rogers MF Avigan ZM Flores MS Samuel M Rattu MA Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen? Expert Rev Hematol 2026 19 4 361 72 10.1080/17474086.2026.2634283 41708325 Lowy JA, Rogers MF, Avigan ZM, Flores MS, Samuel M, Rattu MA, et al. Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen? Expert Rev Hematol. 2026;19(4):361–72. 10.1080/17474086.2026.2634283. 41708325 10.1080/17474086.2026.2634283

63. Avigan ZM Rattu MA Richter J An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma Expert Opin Biol Ther 2025 25 3 221 28 10.1080/14712598.2025.2465825 39923122 Avigan ZM, Rattu MA, Richter J. An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma. Expert Opin Biol Ther. 2025;25(3):221–28. 10.1080/14712598.2025.2465825. 39923122 10.1080/14712598.2025.2465825

64. Jona Á Tothfalusi D Illes Á Miltenyi Z Bispecific antibodies in B-Cell lymphomas: mechanisms, efficacy, toxicity, and management Medicina (Kaunas) 2026 62 2 342 10.3390/medicina62020342 41752741 PMC12942362 Jona Á, Tothfalusi D, Illes Á, Miltenyi Z. Bispecific antibodies in B-Cell lymphomas: mechanisms, efficacy, toxicity, and management. Medicina (Kaunas). 2026;62(2):342. 10.3390/medicina62020342. 41752741 10.3390/medicina62020342 PMC12942362

65. Ding YE Zhong YR Zhang LS Xu L Li J Wen Y Lipid metabolism reprogramming in diffuse large B-Cell lymphoma (DLBCL): mechanisms and treatment strategies Cancers (Basel) 2026 18 4 701 10.3390/cancers18040701 41749954 PMC12939001 Ding YE, Zhong YR, Zhang LS, Xu L, Li J, Wen Y. Lipid metabolism reprogramming in diffuse large B-Cell lymphoma (DLBCL): mechanisms and treatment strategies. Cancers (Basel). 2026;18(4):701. 10.3390/cancers18040701. 41749954 10.3390/cancers18040701 PMC12939001

66. Kobayashi T Chimeric antigen receptor T-cell and bispecific antibody therapies for follicular lymphoma: recent advances and future prospects JCEH 2025 65 4 253 58 10.3960/jslrt.25050 41443881 PMC12883024 Kobayashi T. Chimeric antigen receptor T-cell and bispecific antibody therapies for follicular lymphoma: recent advances and future prospects. JCEH. 2025;65(4):253–58. 10.3960/jslrt.25050. 41443881 10.3960/jslrt.25050 PMC12883024

67. Wespiser M Gille R Perol M ROS1-positive non-small cell lung cancer: from genomics to treatment decisions Front Oncol 2026 16 1739598 10.3389/fonc.2026.1739598 41704605 PMC12907153 Wespiser M, Gille R, Perol M. ROS1-positive non-small cell lung cancer: from genomics to treatment decisions. Front Oncol. 2026;16:1739598. 10.3389/fonc.2026.1739598. 41704605 10.3389/fonc.2026.1739598 PMC12907153

68. Bischoff H Gendarme S Somme L Chouaid C Schott R Evolving Therapeutic landscape of ROS1-positive non-Small cell lung cancer: an updated review Curr Oncol 2025 32 11 626 10.3390/curroncol32110626 41294688 PMC12650809 Bischoff H, Gendarme S, Somme L, Chouaid C, Schott R. Evolving therapeutic landscape of ROS1-positive non-small cell lung cancer: an updated review. Curr Oncol. 2025;32(11):626. 10.3390/curroncol32110626. 41294688 10.3390/curroncol32110626 PMC12650809

69. Desilets A, Repetto M, Yang SR, Drilon A. Targeting ROS1 rearrangements in non–small cell lung cancer: current insights and future directions. Cancer. 2025;131(Suppl S1):e35784. 10.1002/cncr.35784. 10.1002/cncr.35784 PMC12551656 40171848

70. Oh JJ Hong SK Contemporary management of metastatic urothelial carcinoma Investig Clin Urol 2025 66 5 375 82 10.4111/icu.20250008 40897656 PMC12437573 Oh JJ, Hong SK. Contemporary management of metastatic urothelial carcinoma. Investig Clin Urol. 2025;66(5):375–82. 10.4111/icu.20250008. 40897656 10.4111/icu.20250008 PMC12437573

71. Li R Linscott J Catto JWF Daneshmand S Faltas BM Kamat AM FGFR inhibition in Urothelial Carcinoma Eur Urology 2025 87 2 110 22 10.1016/j.eururo.2024.09.012 39353825 Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, et al. FGFR inhibition in urothelial carcinoma. Eur Urology. 2025;87(2):110–22. 10.1016/j.eururo.2024.09.012. 10.1016/j.eururo.2024.09.012 39353825

72. Du J Shen H Zeng T Liu W Xie Y Targeted therapies for urothelial carcinoma: from FGFR inhibitors to next‑generation antibody-drug conjugates (review) Int J Oncol 2025 68 2 1 17 10.3892/ijo.2025.5841 41456439 PMC12742833 Du J, Shen H, Zeng T, Liu W, Xie Y. Targeted therapies for urothelial carcinoma: from FGFR inhibitors to next‑generation antibody-drug conjugates (review). Int J Oncol. 2025;68(2):1–17. 10.3892/ijo.2025.5841. 41456439 10.3892/ijo.2025.5841 PMC12742833

73. Roubal K Myint ZW Kolesar JM Erdafitinib: a novel therapy for FGFR-mutated urothelial cancer Am J Health-System Pharm 2020 77 5 346 51 10.1093/ajhp/zxz329 32073123 Roubal K, Myint ZW, Kolesar JM. Erdafitinib: a novel therapy for FGFR-mutated urothelial cancer. Am J Health-System Pharm. 2020;77(5):346–51. 10.1093/ajhp/zxz329. 10.1093/ajhp/zxz329 32073123

74. Lu Y Xu M Chen X Xu H Sun N Weisgerber KE Neurofibromatosis type 1: genetic mechanisms and advances in Therapeutic innovation Cancers (Basel) 2025 17 23 3788 10.3390/cancers17233788 41374990 PMC12691366 Lu Y, Xu M, Chen X, Xu H, Sun N, Weisgerber KE, et al. Neurofibromatosis type 1: genetic mechanisms and advances in therapeutic innovation. Cancers (Basel). 2025;17(23):3788. 10.3390/cancers17233788. 41374990 10.3390/cancers17233788 PMC12691366

75. Oztosun G Armstrong A Hirbe AC Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas Expert Opin Investigational Drugs 2025 34 9 665 73 10.1080/13543784.2025.2558656 40932001 Oztosun G, Armstrong A, Hirbe AC. Mirdametinib, an FDA-approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas. Expert Opin Investigational Drugs. 2025;34(9):665–73. 10.1080/13543784.2025.2558656. 10.1080/13543784.2025.2558656 40932001

76. Phillips KA, Schiff D. Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas. Expert Rev Anticancer Ther. 2026;1–9. 10.1080/14737140.2026.2645395. 10.1080/14737140.2026.2645395 41816962

77. Zhu R Zhang H Zhang F Mechanistic optimization of inavolisib combined with CDK4/6 inhibitors in the treatment of PIK3CA-mutated breast tumors Front. Immunol 2025 16 1693927 10.3389/fimmu.2025.1693927 41280894 PMC12631382 Zhu R, Zhang H, Zhang F. Mechanistic optimization of inavolisib combined with CDK4/6 inhibitors in the treatment of PIK3CA-mutated breast tumors. Front. Immunol. 2025;16:1693927. 10.3389/fimmu.2025.1693927. 41280894 10.3389/fimmu.2025.1693927 PMC12631382

78. Hao C Wei Y Meng W Zhang J Yang X PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer Cancer Treat Rev 2025 132 102861 10.1016/j.ctrv.2024.102861 39662202 Hao C, Wei Y, Meng W, Zhang J, Yang X. PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treat Rev. 2025;132:102861. 10.1016/j.ctrv.2024.102861. 39662202 10.1016/j.ctrv.2024.102861

79. Choate KA Pratt EPS Jennings MJ Winn RJ Mann PB IDH mutations in glioma: molecular, cellular, diagnostic, and clinical implications Biol (Basel) 2024 13 11 885 10.3390/biology13110885 PMC11592129 39596840 Choate KA, Pratt EPS, Jennings MJ, Winn RJ, Mann PB. IDH mutations in glioma: molecular, cellular, diagnostic, and clinical implications. Biol (Basel). 2024;13(11):885. 10.3390/biology13110885. 10.3390/biology13110885 PMC11592129 39596840

80. Mi de la Fuente Touat M Mj van den Bent Preusser M Peters KB Young RJ The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma Neuro-Oncology 2025 27 5 1135 48 10.1093/neuonc/noae259 39723472 PMC12187374 de la Fuente Mi, Touat M, van den Bent Mj, Preusser M, Peters KB, Young RJ, et al. The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. Neuro-Oncology. 2025;27(5):1135–48. 10.1093/neuonc/noae259. 39723472 10.1093/neuonc/noae259 PMC12187374

81. Ruda R Bruno F Pellerino A Pronello E Soffietti R Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors Expert Opin Pharmacother 2025 26 10 1163 75 10.1080/14656566.2025.2516617 40479721 Ruda R, Bruno F, Pellerino A, Pronello E, Soffietti R. Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors. Expert Opin Pharmacother. 2025;26(10):1163–75. 10.1080/14656566.2025.2516617. 40479721 10.1080/14656566.2025.2516617

82. Rossi J, Picca A, Santonocito OS, Schembari S, Testaverde L, Sanson M, et al. Advances in the management of patients with IDH-mutant glioma. Oncologist. 2025;30(12):oyaf391. 10.1093/oncolo/oyaf391. 10.1093/oncolo/oyaf391 PMC12712973 41284931

83. Seyve A Ducray F Open questions on vorasidenib Curr Opin Oncol 2025 37 6 589 94 10.1097/CCO.0000000000001193 41029964 Seyve A, Ducray F. Open questions on vorasidenib. Curr Opin Oncol. 2025;37(6):589–94. 10.1097/CCO.0000000000001193. 41029964 10.1097/CCO.0000000000001193

84. Caronna E Alpuente A Torres-Ferrus M Pozo-Rosich P CGRP monoclonal antibodies and CGRP receptor antagonists (gepants) in migraine prevention Handb Clin Neurol 2024 199 107 24 10.1016/B978-0-12-823357-3.00024-0 38307640 Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. CGRP monoclonal antibodies and CGRP receptor antagonists (gepants) in migraine prevention. Handb Clin Neurol. 2024;199:107–24. 10.1016/B978-0-12-823357-3.00024-0. 38307640 10.1016/B978-0-12-823357-3.00024-0

85. Jakubowska B Sowa-Kucma M Gepants: targeting the CGRP pathway for migraine relief Front Pharmacol 2025 16 1708226 10.3389/fphar.2025.1708226 41357877 PMC12678924 Jakubowska B, Sowa-Kucma M. Gepants: targeting the CGRP pathway for migraine relief. Front Pharmacol. 2025;16:1708226. 10.3389/fphar.2025.1708226. 41357877 10.3389/fphar.2025.1708226 PMC12678924

86. Ladhwani NK Bai P Lal R Shah AM Bai S Ahmed GU The role of atogepant in migraine prevention: a systematic review and meta-analysis BMC Neurol 2025 25 1 375 10.1186/s12883-025-04394-z 40898163 PMC12406345 Ladhwani NK, Bai P, Lal R, Shah AM, Bai S, Ahmed GU, et al. The role of atogepant in migraine prevention: a systematic review and meta-analysis. BMC Neurol. 2025;25(1):375. 10.1186/s12883-025-04394-z. 40898163 10.1186/s12883-025-04394-z PMC12406345

87. Bauer AJ Auble B Clark AL Hu TY Isaza A McNerney KP Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review Front Pediatr 2024 12 1444919 10.3389/fped.2024.1444919 39132310 PMC11310894 Bauer AJ, Auble B, Clark AL, Hu TY, Isaza A, McNerney KP, et al. Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review. Front Pediatr. 2024;12:1444919. 10.3389/fped.2024.1444919. 39132310 10.3389/fped.2024.1444919 PMC11310894

88. Markova B, Mayerl S, Heuer H. Toward a treatment for thyroid hormone transporter MCT8 deficiency – achievements and challenges. Eur Thyroid J. 2024;13(6):e240286. 10.1530/ETJ-24-0286. 10.1530/ETJ-24-0286 PMC11623285 39485732

89. Garcia-Aldea Á, Guillen-Yunta M, Valcarcel-Hernandez V, Montero-Pedrazuela A, Guadano-Ferraz A, Barez-Lopez S. Insights on the role of thyroid hormone transport in neurosensory organs and implication for the Allan–Herndon–Dudley syndrome. Eur Thyroid J. 2024;13(2):e230241. 10.1530/ETJ-23-0241. 10.1530/ETJ-23-0241 PMC10959056 38417253

90. Gensthaler BM Gräfe KA Rößler A Siebenand S Die neuen Arzneistoffe 2025 [The new drugs 2025] Pharm Ztg 2026 171 4 4 50 Gensthaler BM, Gräfe KA, Rößler A, Siebenand S. Die neuen Arzneistoffe 2025 [The new drugs 2025]. Pharm Ztg. 2026, Suppl. to 171(4):4–50.

91. Gemeinsamer Bundesausschuss: benefit assessment of medicinal products. https://www.g-ba.de/english/benefitassessment/ . Accessed 11 May 2026.

92. European Medicines Agency: Copiktra ® (duvelisib) - summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra . Accessed 26 May 2026.

93. Long P Li S Pan L Wang Y Chen W Wang X Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database Front Pharmacol 2024 15 1378010 10.3389/fphar.2024.1378010 38766629 PMC11099241 Long P, Li S, Pan L, Wang Y, Chen W, Wang X. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database. Front Pharmacol. 2024;15:1378010. 10.3389/fphar.2024.1378010. 38766629 10.3389/fphar.2024.1378010 PMC11099241

94. Kawakami H Nakanishi K Makiyama A Konishi H Morita S Narita Y Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study) Gastric Cancer 2025 28 1 51 61 10.1007/s10120-024-01555-w 39387986 PMC11706843 Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, et al. Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study). Gastric Cancer. 2025;28(1):51–61. 10.1007/s10120-024-01555-w. 39387986 10.1007/s10120-024-01555-w PMC11706843

95. Alrosan AZ Dmour I Rataan AO Heilat GB Alrosan K Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: two recently developed chemotherapies in the crucial battle against breast cancer Toxicol Rep 2025 14 102054 10.1016/j.toxrep.2025.102054 40502326 PMC12152638 Alrosan AZ, Dmour I, Rataan AO, Heilat GB, Alrosan K. Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: two recently developed chemotherapies in the crucial battle against breast cancer. Toxicol Rep. 2025;14:102054. 10.1016/j.toxrep.2025.102054. 40502326 10.1016/j.toxrep.2025.102054 PMC12152638

96. Cecco S Puligheddu S Fusaroli M Gerratana L Yan M Zamagni C Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system Targ Oncol 2024 19 3 435 45 10.1007/s11523-024-01058-9 PMC11111510 38696126 Cecco S, Puligheddu S, Fusaroli M, Gerratana L, Yan M, Zamagni C, et al. Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA Adverse Event Reporting System. Targ Oncol. 2024;19(3):435–45. 10.1007/s11523-024-01058-9. 10.1007/s11523-024-01058-9 PMC11111510 38696126

97. Kanbayashi Y Morioka R Takayama K Hosohata K Disproportionality analysis of gastrointestinal adverse events associated with trastuzumab deruxtecan using the Japanese adverse Drug event report database In Vivo 2025 39 6 3453 60 10.21873/invivo.14143 41167674 PMC12588195 Kanbayashi Y, Morioka R, Takayama K, Hosohata K. Disproportionality analysis of gastrointestinal adverse events associated with trastuzumab deruxtecan using the Japanese Adverse Drug Event Report database. In Vivo. 2025;39(6):3453–60. 10.21873/invivo.14143. 41167674 10.21873/invivo.14143 PMC12588195

98. European Medicines Agency: Enhertu ® (trastuzumab deruxtecan) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf . Accessed 27 May 2026.

99. Yu M Zhou L Cao M Ji C Zheng Y Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database Front. Immunol 2024 15 1397692 10.3389/fimmu.2024.1397692 39234238 PMC11372787 Yu M, Zhou L, Cao M, Ji C, Zheng Y. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database. Front. Immunol. 2024;15:1397692. 10.3389/fimmu.2024.1397692. 39234238 10.3389/fimmu.2024.1397692 PMC11372787

100. Kilton MM Wei EX Georgeson CJ Hirner JP Post-market surveillance data demonstrate high mortality associated with enfortumab vedotin skin toxicity, not worsened by immune checkpoint inhibitors or corticosteroids J Am Acad Dermatol 2026 94 3 942 44 10.1016/j.jaad.2025.10.134 41183712 Kilton MM, Wei EX, Georgeson CJ, Hirner JP. Post-market surveillance data demonstrate high mortality associated with enfortumab vedotin skin toxicity, not worsened by immune checkpoint inhibitors or corticosteroids. J Am Acad Dermatol. 2026;94(3):942–44. 10.1016/j.jaad.2025.10.134. 41183712 10.1016/j.jaad.2025.10.134

101. European Medicines Agency: Padcev ® (enfortumab vedotin) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/padcev-epar-product-information_en.pdf . Accessed 27 May 2026.

102. Fu X Zeng D Li M Wu J Yang Y Mao Q Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system Expert Opin Drug Saf 2026 25 7 1309 17 10.1080/14740338.2025.2471512 40001304 Fu X, Zeng D, Li M, Wu J, Yang Y, Mao Q, et al. Post-marketing safety surveillance of amivantamab: a real world study based on the FDA Adverse Event Reporting System. Expert Opin Drug Saf. 2026;25(7):1309–17. 10.1080/14740338.2025.2471512. 40001304 10.1080/14740338.2025.2471512

103. Sun R Ning Z Qin H Zhang W Teng Y Jin C A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database Sci Rep 2024 14 1 9552 10.1038/s41598-024-55829-5 38664423 PMC11045761 Sun R, Ning Z, Qin H, Zhang W, Teng Y, Jin C, et al. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA Adverse Event Reporting System (FAERS) database. Sci Rep. 2024;14(1):9552. 10.1038/s41598-024-55829-5. 38664423 10.1038/s41598-024-55829-5 PMC11045761

104. Zeng Y, Li Y, Du Z, Shu R, Fu C, Zeng Q. Cutaneous adverse events associated with rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024. Naunyn Schmiedebergs Arch Pharmacol. 2026. 10.1007/s00210-026-05168-1. 10.1007/s00210-026-05168-1 41790218

105. Zhang J Li W Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer BMC Pulm Med 2025 25 1 63 10.1186/s12890-025-03509-z 39915804 PMC11800505 Zhang J, Li W. Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. BMC Pulm Med. 2025;25(1):63. 10.1186/s12890-025-03509-z. 39915804 10.1186/s12890-025-03509-z PMC11800505

106. European Medicines Agency: Rybrevant ® (amivantamab) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf . Accessed 27 May 2026.

107. Le X Zhang Y Ma J Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database Expert Opin Drug Saf 2025 24 7 821 30 10.1080/14740338.2025.2470875 39982395 Le X, Zhang Y, Ma J. Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database. Expert Opin Drug Saf. 2025;24(7):821–30. 10.1080/14740338.2025.2470875. 39982395 10.1080/14740338.2025.2470875

108. Cicala G Russo G Santoro V Franchina T Silvestris N Santarpia M Neuropsychiatric adverse events with monoclonal antibodies approved for multiple myeloma: an analysis from the FDA adverse event reporting system Pharmaceuticals (Basel) 2024 17 10 1266 10.3390/ph17101266 39458907 PMC11510275 Cicala G, Russo G, Santoro V, Franchina T, Silvestris N, Santarpia M, et al. Neuropsychiatric adverse events with monoclonal antibodies approved for multiple myeloma: an analysis from the FDA Adverse Event Reporting System. Pharmaceuticals (Basel). 2024;17(10):1266. 10.3390/ph17101266. 39458907 10.3390/ph17101266 PMC11510275

109. European Medicines Agency: Talvey ® (talquetamab) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/talvey-epar-product-information_en.pdf . Accessed 27 May 2026.

110. European Medicines Agency: Tecvayli ® (teclistamab) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf . Accessed 27 May 2026.

111. European Medicines Agency: Elrexfio ® (elranatamab) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/elrexfio-epar-product-information_en.pdf . Accessed 27 May 2026.

112. Zhou M, Jiang C, Su C. Exploration of adverse event profiles for glofitamab: a disproportionality analysis using the FDA Adverse Event Reporting System. PLoS One. 2025;20(11):e0336151. 10.1371/journal.pone.0336151. 10.1371/journal.pone.0336151 PMC12585042 41187120

113. European Medicines Agency: Columvi ® (glofitamab) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/columvi-epar-product-information_en.pdf . Accessed 27 May 2026.

114. European Medicines Agency: Tepkinly ® (epcoritamab) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/tepkinly-epar-product-information_en.pdf . Accessed 27 May 2026.

115. European Medicines Agency: Lunsumio ® (mosunetuzumab) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf . Accessed 27 May 2026.

116. European Medicines Agency: Kimmtrak ® (tebentafusp) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/kimmtrak-epar-product-information_en.pdf . Accessed 27 May 2026.

117. Xu Y, Wang D, Xu Y. A real-world pharmacovigilance study of fruquintinib based on the FDA Adverse Event Reporting System (FAERS) database. Cancer Med. 2025;14(21):e71352. 10.1002/cam4.71352. 10.1002/cam4.71352 PMC12593544 41201183

118. Liu C, Zhang H. Post-marketing signal detection of fruquintinib-associated adverse events using the FAERS database. Med (Baltim). 2026;105(14):e48239. 10.1097/MD.0000000000048239. 10.1097/MD.0000000000048239 PMC13052964 41931348

119. European Medicines Agency: Fruzaqla ® (fruquintinib) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/fruzaqla-epar-product-information_en.pdf . Accessed 27 May 2026.

120. Li P Wu L Song Z Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database Sci Rep 2025 15 1 26150 10.1038/s41598-025-11411-1 40681604 PMC12274456 Li P, Wu L, Song Z. Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database. Sci Rep. 2025;15(1):26150. 10.1038/s41598-025-11411-1. 40681604 10.1038/s41598-025-11411-1 PMC12274456

121. European Medicines Agency: Lytgobi ® (futibatinib) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf . Accessed 27 May 2026.

122. Zhan J Lei Z Xu Y Cen J Tang X Wan M Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study J Dermatolog Treat 2026 37 1 2647604 10.1080/09546634.2026.2647604 41918293 Zhan J, Lei Z, Xu Y, Cen J, Tang X, Wan M. Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study. J Dermatolog Treat. 2026;37(1):2647604. 10.1080/09546634.2026.2647604. 41918293 10.1080/09546634.2026.2647604

123. Huang Y Ke C Chen M Safety assessment of ritlecitinib based on the FDA adverse event reporting system (FAERS) database: a real-world pharmacovigilance study J Dermatol 2025 52 10 1561 69 10.1111/1346-8138.17886 40715010 Huang Y, Ke C, Chen M. Safety assessment of ritlecitinib based on the FDA adverse event reporting system (FAERS) database: a real-world pharmacovigilance study. J Dermatol. 2025;52(10):1561–69. 10.1111/1346-8138.17886. 40715010 10.1111/1346-8138.17886

124. Altinoz Guney C Koc HA Investigation of infection risk associated with janus kinase inhibitors: a pharmacovigilance analysis using the food and Drug Administration’s adverse event reporting system database Clin Exp Dermatol 2026 51 2 226 35 10.1093/ced/llaf427 40974167 Altinoz Guney C, Koc HA. Investigation of infection risk associated with janus kinase inhibitors: a pharmacovigilance analysis using the Food and Drug Administration’s Adverse Event Reporting System database. Clin Exp Dermatol. 2026;51(2):226–35. 10.1093/ced/llaf427. 40974167 10.1093/ced/llaf427

125. European Medicines Agency: Litfulo ® (ritlecitinib) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/litfulo-epar-product-information_en.pdf . Accessed 26 May 2026.

126. Che X Zhu Y Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS) Front Pharmacol 2025 16 1561937 10.3389/fphar.2025.1561937 40642018 PMC12242178 Che X, Zhu Y. Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA Adverse Event Reporting System (FAERS). Front Pharmacol. 2025;16:1561937. 10.3389/fphar.2025.1561937. 40642018 10.3389/fphar.2025.1561937 PMC12242178

127. Feng Y Fa X Wang Y Zhang T Sun X Li F A real-world disproportionality analysis of ripretinib data mining of the public version of FDA adverse event reporting system Front Pharmacol 2025 16 1469597 10.3389/fphar.2025.1469597 40170718 PMC11959022 Feng Y, Fa X, Wang Y, Zhang T, Sun X, Li F. A real-world disproportionality analysis of ripretinib data mining of the public version of FDA Adverse Event Reporting System. Front Pharmacol. 2025;16:1469597. 10.3389/fphar.2025.1469597. 40170718 10.3389/fphar.2025.1469597 PMC11959022

128. Hu Y Zhang L Gong Q Huang L Yin C Miao Y Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database Front Pharmacol 2025 16 1481114 10.3389/fphar.2025.1481114 40078281 PMC11896992 Hu Y, Zhang L, Gong Q, Huang L, Yin C, Miao Y, et al. Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database. Front Pharmacol. 2025;16:1481114. 10.3389/fphar.2025.1481114. 40078281 10.3389/fphar.2025.1481114 PMC11896992

129. Wang S Chen H Zhou Y Chen J Cao J Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system Front Oncol 2025 15 1542315 10.3389/fonc.2025.1542315 40231257 PMC11994415 Wang S, Chen H, Zhou Y, Chen J, Cao J. Safety assessment of ripretinib: a real-world adverse event analysis from the Food and Drug Administration Adverse Event Reporting System. Front Oncol. 2025;15:1542315. 10.3389/fonc.2025.1542315. 40231257 10.3389/fonc.2025.1542315 PMC11994415

130. Ma Y Fan A Wang Y Xu S Liu X Yang J Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system Front Oncol 2025 15 1608451 10.3389/fonc.2025.1608451 40951360 PMC12428477 Ma Y, Fan A, Wang Y, Xu S, Liu X, Yang J. Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA Adverse Event Reporting System. Front Oncol. 2025;15:1608451. 10.3389/fonc.2025.1608451. 40951360 10.3389/fonc.2025.1608451 PMC12428477

131. European Medicines Agency: Qinlock ® (ripretinib) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/qinlock-epar-product-information_en.pdf . Accessed 27 May 2026.

132. Eugene AR Country-specific psychopharmacological risk of reporting suicidality comparing 38 antidepressants and lithium from the FDA adverse event reporting system, 2017–2023 Front Psychiatry 2024 15 1442490 10.3389/fpsyt.2024.1442490 39575192 PMC11580034 Eugene AR. Country-specific psychopharmacological risk of reporting suicidality comparing 38 antidepressants and lithium from the FDA Adverse Event Reporting System, 2017–2023. Front Psychiatry. 2024;15:1442490. 10.3389/fpsyt.2024.1442490. 39575192 10.3389/fpsyt.2024.1442490 PMC11580034

133. Caruso I Di Gioia L Di Molfetta S Caporusso M Cignarelli A Sorice GP The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database J Endocrinol Invest 2024 47 11 2671 78 10.1007/s40618-024-02441-z 39141075 PMC11473560 Caruso I, Di Gioia L, Di Molfetta S, Caporusso M, Cignarelli A, Sorice GP, et al. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. J Endocrinol Invest. 2024;47(11):2671–78. 10.1007/s40618-024-02441-z. 39141075 10.1007/s40618-024-02441-z PMC11473560

134. Gu S Adverse events associated with Tirzepatide: updated pharmacovigilance analysis using FAERS (2022 Q1-2025 Q1) with an adapted time-to-onset method DHPS 2026 18 1 13 10.2147/DHPS.S556918 PMC12989282 41531800 Gu S. Adverse events associated with tirzepatide: updated pharmacovigilance analysis using FAERS (2022 Q1-2025 Q1) with an adapted time-to-onset method. DHPS. 2026;18:1–13. 10.2147/DHPS.S556918. 10.2147/DHPS.S556918 PMC12989282 41531800

135. Correa LMA Mazur GR Santiago CBG Dante LE de Marco PS Ferres PBS Tirzepatide in solid organ transplant recipients: early real-world signals of efficacy and safety—A narrative review Transpl Rev 2026 40 2 101003 10.1016/j.trre.2026.101003 41707409 Correa LMA, Mazur GR, Santiago CBG, Dante LE, de Marco PS, Ferres PBS. Tirzepatide in solid organ transplant recipients: early real-world signals of efficacy and safety - a narrative review. Transpl Rev. 2026;40(2):101003. 10.1016/j.trre.2026.101003. 10.1016/j.trre.2026.101003 41707409

136. Almansour HA Thaibah HA Alfarhan M Al-Qahtani SA Khardali AA Alshammari TM Real-world safety concerns of Tirzepatide: a retrospective analysis of FAERS data (2022–2025) Healthcare (Basel) 2025 13 18 2259 10.3390/healthcare13182259 41008391 PMC12469573 Almansour HA, Thaibah HA, Alfarhan M, Al-Qahtani SA, Khardali AA, Alshammari TM. Real-world safety concerns of tirzepatide: a retrospective analysis of FAERS data (2022–2025). Healthcare (Basel). 2025;13(18):2259. 10.3390/healthcare13182259. 41008391 10.3390/healthcare13182259 PMC12469573

137. Chen D Wang Z Xie Z Chen Y Luo S Xu S Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events Front Pharmacol 2026 17 1785129 10.3389/fphar.2026.1785129 41948731 PMC13050862 Chen D, Wang Z, Xie Z, Chen Y, Luo S, Xu S. Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events. Front Pharmacol. 2026;17:1785129. 10.3389/fphar.2026.1785129. 41948731 10.3389/fphar.2026.1785129 PMC13050862

138. Makkena HB. Comparative gynecological safety of the dual GIP/GLP-1 receptor agonist tirzepatide vs. the GLP-1 receptor agonist semaglutide: a real-world pharmacovigilance analysis (2022–2025). Cureus. 2026;18(1):e101738. 10.7759/cureus.101738. 10.7759/cureus.101738 PMC12908611 41704984

139. Wang M Yang Z Yan M Liu S Xiao S Depression and suicide/self-injury signals for weight loss medications: a disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database J Affective Disord 2025 389 119670 10.1016/j.jad.2025.119670 40523410 Wang M, Yang Z, Yan M, Liu S, Xiao S. Depression and suicide/self-injury signals for weight loss medications: a disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database. J Affective Disord. 2025;389:119670. 10.1016/j.jad.2025.119670. 10.1016/j.jad.2025.119670 40523410

140. Gandhi A Bhatt N Parhizgar A Comparative renal safety of Tirzepatide and semaglutide: an FDA adverse event reporting system (FAERS)—disproportionality study JCM 2025 14 21 7678 10.3390/jcm14217678 41227073 PMC12610529 Gandhi A, Bhatt N, Parhizgar A. Comparative renal safety of tirzepatide and semaglutide: an FDA Adverse Event Reporting System (FAERS)—disproportionality study. JCM. 2025;14(21):7678. 10.3390/jcm14217678. 41227073 10.3390/jcm14217678 PMC12610529

141. Seijas-Amigo J Salgado-Barreira Á Rodriguez-Penas D Cardeso-Paredes B Ribeiro-Ferreiro M Rodriguez-Manero M Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA adverse event reporting system Int J Clin Pharm 2026 48 3 1026 35 10.1007/s11096-026-02099-y 41739406 PMC13176177 Seijas-Amigo J, Salgado-Barreira Á, Rodriguez-Penas D, Cardeso-Paredes B, Ribeiro-Ferreiro M, Rodriguez-Manero M, et al. Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System. Int J Clin Pharm. 2026;48(3):1026–35. 10.1007/s11096-026-02099-y. 41739406 10.1007/s11096-026-02099-y PMC13176177

142. Fahim SA Attia YM Messiha A Nabawy AY Refaat F El-Maadawy WH Comparative safety and side effects of semaglutide and tirzepatide: implications for clinical decision-making in obesity management Biomed Pharmacother 2025 193 118731 10.1016/j.biopha.2025.118731 41177120 Fahim SA, Attia YM, Messiha A, Nabawy AY, Refaat F, El-Maadawy WH. Comparative safety and side effects of semaglutide and tirzepatide: implications for clinical decision-making in obesity management. Biomed Pharmacother. 2025;193:118731. 10.1016/j.biopha.2025.118731. 41177120 10.1016/j.biopha.2025.118731

143. Chen H Ding Y Shan Y Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database Expert Opin Drug Saf 2025 24 8 959 67 10.1080/14740338.2025.2468860 40037695 Chen H, Ding Y, Shan Y. Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database. Expert Opin Drug Saf. 2025;24(8):959–67. 10.1080/14740338.2025.2468860. 40037695 10.1080/14740338.2025.2468860

144. Lakhani M Kwan ATH Mihalache A Popovic MM Nanji K Xie JS Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries Am J Ophthalmol 2025 277 148 68 10.1016/j.ajo.2025.05.007 40383360 Lakhani M, Kwan ATH, Mihalache A, Popovic MM, Nanji K, Xie JS, et al. Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries. Am J Ophthalmol. 2025;277:148–68. 10.1016/j.ajo.2025.05.007. 40383360 10.1016/j.ajo.2025.05.007

145. Hankosky ER Chinthammit C Meeks A Huang A Ward JM Mojdami D Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the optum market clarity database Diabetes Obes Metab 2025 27 5 2810 21 10.1111/dom.16290 39996368 PMC11964993 Hankosky ER, Chinthammit C, Meeks A, Huang A, Ward JM, Mojdami D, et al. Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the optum market clarity database. Diabetes Obes Metab. 2025;27(5):2810–21. 10.1111/dom.16290. 39996368 10.1111/dom.16290 PMC11964993

146. Gong J Gao F Jiang K Xie Q Zhao X Lei Z Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: a meta-analysis J Diabetes Invest 2025 16 1 83 92 10.1111/jdi.14340 PMC11693576 39569606 Gong J, Gao F, Jiang K, Xie Q, Zhao X, Lei Z. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: a meta-analysis. J Diabetes Invest. 2025;16(1):83–92. 10.1111/jdi.14340. 10.1111/jdi.14340 PMC11693576 39569606

147. Gregory V Mollan SP Are synthetic incretins associated with ischaemic optic neuropathy? Eye (Lond) 2025 39 5 808 09 10.1038/s41433-025-03718-0 39955376 PMC11933427 Gregory V, Mollan SP. Are synthetic incretins associated with ischaemic optic neuropathy? Eye (Lond). 2025;39(5):808–09. 10.1038/s41433-025-03718-0. 39955376 10.1038/s41433-025-03718-0 PMC11933427

148. Katz BJ Lee MS Lincoff NS Abel AS Chowdhary S Ellis BD Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide JAMA Ophthalmol 2025 143 3 215 20 10.1001/jamaophthalmol.2024.6058 39883468 PMC11783245 Katz BJ, Lee MS, Lincoff NS, Abel AS, Chowdhary S, Ellis BD, et al. Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide. JAMA Ophthalmol. 2025;143(3):215–20. 10.1001/jamaophthalmol.2024.6058. 39883468 10.1001/jamaophthalmol.2024.6058 PMC11783245

149. European Medicines Agency: Mounjaro ® (tirzepatide) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf . Accessed 27 May 2026.

150. Wu Y Ke W Li H A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod Front Pharmacol 2025 16 1693090 10.3389/fphar.2025.1693090 41306780 PMC12644091 Wu Y, Ke W, Li H. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for etrasimod. Front Pharmacol. 2025;16:1693090. 10.3389/fphar.2025.1693090. 41306780 10.3389/fphar.2025.1693090 PMC12644091

151. Guo Q Shan M Gao W Safety evaluation of etrasimod for ulcerative colitis based on the FAERS database Sci Rep 2025 15 1 36558 10.1038/s41598-025-19679-z 41120400 PMC12541039 Guo Q, Shan M, Gao W. Safety evaluation of etrasimod for ulcerative colitis based on the FAERS database. Sci Rep. 2025;15(1):36558. 10.1038/s41598-025-19679-z. 41120400 10.1038/s41598-025-19679-z PMC12541039

152. European Medicines Agency: Velsipity ® (etrasimod) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/velsipity-epar-product-information_en.pdf . Accessed 27 May 2026.

153. Fan H Yang Y Li J Huang Z Zhou B Comprehensive analysis of sparsentan-related adverse events: latest insights from VigiAccess and FAERS J Nephrol 2025 38 9 2881 91 10.1007/s40620-025-02412-4 41023522 Fan H, Yang Y, Li J, Huang Z, Zhou B. Comprehensive analysis of sparsentan-related adverse events: latest insights from VigiAccess and FAERS. J Nephrol. 2025;38(9):2881–91. 10.1007/s40620-025-02412-4. 41023522 10.1007/s40620-025-02412-4

154. Fu W Wang J Xue Y Pan D Real-world assessment of sparsentan’s drug safety framework Ren Fail 2025 47 1 2461668 10.1080/0886022X.2025.2461668 39972562 PMC11843636 Fu W, Wang J, Xue Y, Pan D. Real-world assessment of sparsentan’s drug safety framework. Ren Fail. 2025;47(1):2461668. 10.1080/0886022X.2025.2461668. 39972562 10.1080/0886022X.2025.2461668 PMC11843636

155. Lv T, Bao W, Chen S. Assessing the real-world safety of sparsentan for immunoglobulin a nephropathy: insights from a comprehensive analysis of FAERS database. Int Urol Nephrol. 2026. 10.1007/s11255-026-05042-2. 10.1007/s11255-026-05042-2 41667900

156. European Medicines Agency: Filspari ® (sparsentan) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/filspari-epar-product-information_en.pdf . Accessed 27 May 2026.

157. Wang L Chen J Li H Wang L Liu F Jiang X Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network Front. Immunol 2025 16 1667249 10.3389/fimmu.2025.1667249 41132654 PMC12540168 Wang L, Chen J, Li H, Wang L, Liu F, Jiang X. Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network. Front. Immunol. 2025;16:1667249. 10.3389/fimmu.2025.1667249. 41132654 10.3389/fimmu.2025.1667249 PMC12540168

158. European Medicines Agency: Zilbrysq ® (zilucoplan) - summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/zilbrysq-epar-product-information_en.pdf . Accessed 27 May 2026.

159. Rao M, Wu L, Chen H, Wu X, Wang H, Chen Y, et al. Hematological toxicity of anti-tumor antibody-drug conjugates: a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System. PLoS One. 2025;20(10):e0334513. 10.1371/journal.pone.0334513. 10.1371/journal.pone.0334513 PMC12558476 41144385

160. Marni M Simoens D Romero N Jones WK Kaja S Disproportionality analysis of oral toxicities associated with PI3K/AKT/mTOR pathway inhibitors using the FAERS database Pharmaceuticals (Basel) 2025 18 10 1580 10.3390/ph18101580 41155694 PMC12567227 Marni M, Simoens D, Romero N, Jones WK, Kaja S. Disproportionality analysis of oral toxicities associated with PI3K/AKT/mTOR pathway inhibitors using the FAERS database. Pharmaceuticals (Basel). 2025;18(10):1580. 10.3390/ph18101580. 41155694 10.3390/ph18101580 PMC12567227

161. Jin C, Zhang X, Ouyang X, Lou Q. Drug-induced urinary incontinence in pediatric patients: a disproportionality analysis of the FDA Adverse Event Reporting System. Med (Baltim). 2026;105(3):e47250. 10.1097/MD.0000000000047250. 10.1097/MD.0000000000047250 PMC12826208 41560109

162. Lischke R Rauchegger T Haas G Koubek M Nowosielski Y Rehak M Intraocular inflammation after intravitreal injection of faricimab–a case series including one case of bilateral choroidal involvement Int J Ophthalmol 2026 19 1 185 92 10.18240/ijo.2026.01.23 41524001 PMC12782075 Lischke R, Rauchegger T, Haas G, Koubek M, Nowosielski Y, Rehak M, et al. Intraocular inflammation after intravitreal injection of faricimab–a case series including one case of bilateral choroidal involvement. Int J Ophthalmol. 2026;19(1):185–92. 10.18240/ijo.2026.01.23. 41524001 10.18240/ijo.2026.01.23 PMC12782075

163. Zhou X Teng T Zhang Y Del Giovane C Furukawa TA Weisz JR Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis Lancet Psychiatry 2020 7 7 581 601 10.1016/S2215-0366(20)30137-1 32563306 PMC7303954 Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(7):581–601. 10.1016/S2215-0366(20)30137-1. 32563306 10.1016/S2215-0366(20)30137-1 PMC7303954

164. Lin YM Liao KM Yu T Wu JY Lai CC Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study Nat Commun 2025 16 1 4471 10.1038/s41467-025-59616-2 40368924 PMC12078458 Lin YM, Liao KM, Yu T, Wu JY, Lai CC. Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study. Nat Commun. 2025;16(1):4471. 10.1038/s41467-025-59616-2. 40368924 10.1038/s41467-025-59616-2 PMC12078458

165. Wen J, Syed B, Nadora D, How-Volkman C, Bernstein E, Truong A, et al. Tirzepatide versus semaglutide on weight loss in type 2 diabetes patients: a systematic review and meta-analysis of direct comparative studies. Endocrino Diabet Metabol. 2025;8(3):e70045. 10.1002/edm2.70045. 10.1002/edm2.70045 PMC11970626 40184508

166. Aizpurua-Arruti X, Goyenechea E, Isla A, Onatibia-Astibia A, Malet-Larrea A, Gastelurrutia M, et al. Impact of additional monitoring on pharmacovigilance and pharmacists’ role: a scoping review. Pharmacoepidemiol Drug. 2025;34(9):e70201. 10.1002/pds.70201. 10.1002/pds.70201 PMC12355443 40814839